



Universiteit  
Leiden  
The Netherlands

## Quality criteria for in vitro human pluripotent stem cell-derived models of tissue-based cells

Pistollato, F.; Bal-Price, A.; Coecke, S.; Parvatam, S.; Pamies, D.; Czysz, K.; ... ; Stacey, G.

### Citation


Pistollato, F., Bal-Price, A., Coecke, S., Parvatam, S., Pamies, D., Czysz, K., ... Stacey, G. (2022). Quality criteria for in vitro human pluripotent stem cell-derived models of tissue-based cells. *Reproductive Toxicology*, 112, 36-50. doi:10.1016/j.reprotox.2022.06.003

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3563484>

**Note:** To cite this publication please use the final published version (if applicable).



## Quality criteria for in vitro human pluripotent stem cell-derived models of tissue-based cells

Francesca Pistollato<sup>a</sup>, Anna Bal-Price<sup>a</sup>, Sandra Coecke<sup>a</sup>, Surat Parvatam<sup>b</sup>, David Pamies<sup>c,d</sup>, Katherine Czysz<sup>e</sup>, Jie Hao<sup>f,g</sup>, Kehkooi Kee<sup>h</sup>, Adrian Kee Keong Teo<sup>i,j,k,l</sup>, Shuaishuai Niu<sup>f,g</sup>, Anja Wilmes<sup>m</sup>, Lena Smirnova<sup>n</sup>, Christian Freund<sup>o</sup>, Christine Mummery<sup>o</sup>, Glyn Stacey<sup>f,g,p,\*</sup>

<sup>a</sup> European Commission, Joint Research Centre, Ispra, Italy

<sup>b</sup> Centre for Predictive Human Model Systems, Atal Incubation Centre-Centre for Cellular and Molecular Biology, Hyderabad, India

<sup>c</sup> Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland

<sup>d</sup> Swiss Centre for Applied Human Toxicology (SCAHT), 4055 Basel, Switzerland

<sup>e</sup> Fujifilm Cellular Dynamics, Inc., Madison, WI 53711, USA

<sup>f</sup> National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China

<sup>g</sup> Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China

<sup>h</sup> Center for Stem Cell Biology and Regenerative Medicine, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China

<sup>i</sup> Stem Cells and Diabetes Laboratory, Institute of Molecular and Cell Biology, A\*STAR, Singapore 138673, Singapore

<sup>j</sup> Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore

<sup>k</sup> Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore

<sup>l</sup> Precision Medicine Translational Research Programme (TRP), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore

<sup>m</sup> Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Amsterdam Institute of Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

<sup>n</sup> Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

<sup>o</sup> Department of Anatomy and Embryology, Leiden University Medical Center, Leiden 2333 ZC, the Netherlands

<sup>p</sup> International Stem Cell Banking Initiative, Hertfordshire SG88HZ, UK

### ARTICLE INFO

Handling Editor: Anna Price

#### Keywords:

Human pluripotent stem cells  
iPSCs  
Endoderm  
Mesoderm  
Ectoderm  
Quality control criteria  
Readiness level  
In vitro toxicology  
Differentiation  
3D  
GCCP

### ABSTRACT

The advent of the technology to isolate or generate human pluripotent stem cells provided the potential to develop a wide range of human models that could enhance understanding of mechanisms underlying human development and disease. These systems are now beginning to mature and provide the basis for the development of in vitro assays suitable to understand the biological processes involved in the multi-organ systems of the human body, and will improve strategies for diagnosis, prevention, therapies and precision medicine. Induced pluripotent stem cell lines are prone to phenotypic and genotypic changes and donor/clone dependent variability, which means that it is important to identify the most appropriate characterization markers and quality control measures when sourcing new cell lines and assessing differentiated cell and tissue culture preparations for experimental work. This paper considers those core quality control measures for human pluripotent stem cell lines and evaluates the state of play in the development of key functional markers for their differentiated cell derivatives to promote assurance of reproducibility of scientific data derived from pluripotent stem cell-based systems.

## 1. Introduction and background

The discovery of the ability to culture human pluripotent stem cells (hPSCs) in vitro [1] raised the exciting possibility to utilize their capability to generate all of the three germ layers required to build the

human body (Fig. 1). Furthermore, the development of reprogramming technology to generate human induced PSC (hiPSC) lines from somatic cells from any candidate donor [2], has made it possible to generate a diverse range of genotype-bespoke tissue cultures for cutting-edge, basic and applied biomedical research, safety and efficacy studies, or to design

\* Corresponding author at: International Stem Cell Banking Initiative, Hertfordshire SG88HZ, UK.

E-mail address: [glyn.stacey@sscbio.com](mailto:glyn.stacey@sscbio.com) (G. Stacey).

<https://doi.org/10.1016/j.reprotox.2022.06.003>

Received 18 January 2022; Received in revised form 27 May 2022; Accepted 7 June 2022

Available online 11 June 2022

0890-6238/© 2022 Elsevier Inc. All rights reserved.

novel in vitro diagnostic assays and eventually precision therapeutic solutions [3–6].

Furthermore, the capacity to generate such in vitro models from bespoke patients with genetic disorders and syndromes is now showing promise to deliver valuable models of disease conditions, including cardiac disease [7], neurodevelopmental disorders [8,9] and diabetes [10,11].

The generation, characterization and use of many different human stem cell lines from many different donors has shown that variation between cell lines and even clones from the same donor [12,13], can confound interpretation of outcomes in disease modeling assays and potentially pose a risk in the use of the cells in cell therapies. Furthermore, individual stem cell lines show phenotypic variations from one culture preparation to another and may also change due to the appearance of genetic variants [14]. Such variations may be introduced by the culture conditions and indicate that careful control of culture quality is essential for reliable experimental work. It also indicates the need for good method practices, including careful documentation of specific human stem cell line features [15] as captured in Good In Vitro Method Practices (GIVMP) for the development of in vitro methods [16]. Acceptance criteria for hPSC use in therapy and as experimental models, which also include assessment of microbial contamination and cell authenticity, have also been specifically considered for hPSCs [17,18].

It is also important to carefully select markers and functional assays for each specific human stem cell-derived cell type and use phenotypic and/or genotypic characterization methods, which together will promote the development of in vitro cell- or tissue-based test systems that are fit for their specific purpose. Such selection must also include practical considerations such as the complexity, speed and cost of the respective analytical tools used.

Whilst the generic challenges such as microbial contamination, genetic variation, as well as stability, identity and cross-contamination of cell lines are well-described, there are special challenges for stem cell

and tissue-based systems [18,19]. These challenges include lengthy differentiation protocols and differentiation into mixed cell types, which can still complicate the achievement of reproducible models with workable acceptance criteria and tolerances.

Here we have outlined the key techniques for the characterization and quality control (QC) of undifferentiated hPSC cell lines and reviewed the range of methods that may be applied to some representative differentiated hPSC derivatives. We also consider the technology readiness level of each differentiation method and its biomarkers for application in toxicology. Furthermore, we discuss critical issues to consider, in order to promote assurance of reproducibility of scientific data derived from hPSC-based systems.

## 2. Selection of hPSC lines, maintenance and quality criteria

It is now feasible to avoid the time and expense of deriving hiPSCs *de novo* by sourcing cells from the increasing number of professional hPSC resource centers [20]. When hPSC lines are not derived by the local laboratory, it is vital that cells are procured from trusted biobanking sources and are quality controlled prior to supply, rather than obtained from laboratories which do not perform such testing on released cell lines.

Below key parameters involved in hPSC quality control are discussed followed by a summary of minimal testing recommended for hPSC banks. For more detailed information and discussion on the techniques described in the following sections the reader is guided to a number of expert reviews on cell banking, quality control and characterization of hPSC lines including the International Stem Cell Banking Initiative [21], Andrews et al. [17], Oshea et al. [22] and Sullivan et al [23].

### 2.1. Cell line authentication

Historically, important authentication technologies, such as




Fig. 1. Early development of human embryonic stem cells and formation of stem cell endodermal, mesodermal and ectodermal germ layers. Created in BioRender.com.

**Table 1**  
Generic minimum QC tests with examples of helpful methodologies and acceptance criteria.

Characteristic	Type of analysis	Exemplar analytical method/s	Acceptance criteria
Pluripotent stem cell features	Stem Cell/ undifferentiated status/ self-renewal markers (e.g., Oct4, SSEA4, SSEA3, Tra 1–60 and Tra 1–81)	1. Flow cytometry 2. PCR	Predominant in stem cell population (e.g., 80–85% of cells)
	Pluripotency method	1. Embryoid body formation and antibody and or PCR positive for germ layer markers 2. Directed differentiation method 3. Teratoma assay	Evidence of ability to form all three germ layers
Viability	Growth and replication capability	1. Membrane dye exclusion (e.g. trypan blue) 2. Cell attachment and colony growth	1. Majority of cells are viable e.g. > 70% of cells 2. Optimal near confluent culture (50–70%) within 5–7 days
Cell line authenticity	Short Tandem Repeat profile	Multiplex PCR for a number of variable number tandem repeat loci	Profile matches that of original donor cells or early passage hPSCs
Genetic integrity	Chromosome analysis	Giemsa banding karyology, qPCR-based genetic screening	Matches original donor (typically 46 chromosomes) Detection of most common karyotypic abnormalities reported in hPSCs
	Reprogramming vectors in hiPSCs Non-integrating reprogramming methods (e.g., SeV)	qPCR qPCR to assess SeV RNA clearance	Vector expression not detected SeV RNA not detected
Microbiological status	Mycoplasma	1. qPCR 2. Mycoplasma broth and agar sub-culture	1. Test sample negative with a positive limit of detection control 2. No turbidity or colonies observed at prescribed time point (typical maximum of 21 days)
	Viral pathogens	qPCR for a range of serious or prevalent human pathogenic viruses	1. Test sample negative with a positive limit of detection control
	Bacteria and fungi	1. Microbiological broth and agar subculture 2. 16s RNA qPCR <sup>a</sup>	1. No broth turbidity or agar colonies observed at prescribed time point. 2. No fungal/bacterial RNA detected

<sup>a</sup> methods for detection of multiple microbial species using common 16sRNA targets in qPCR are under development and will hopefully provide valuable QC tests in the future.

karyotyping, isoenzyme analysis, immunotyping and human leukocyte antigen typing, have not proven to have sufficient resolving (discriminating) power to enable unambiguous authentication of human cells to the individual donor-genotype level. The unintentional switching of lines or cross-contamination, is a significant threat to the quality of research work and currently the most commonly used technique is short tandem repeat (STR) analysis. This uses PCR to identify differences in STR alleles that are variable between cell lines from different individual donors.

## 2.2. Phenotypic characterization

### 2.2.1. Stem cell biomarkers

Pluripotent stem cells consistently express a common set of markers [24] that are typically characterized with fluorochrome-conjugated antibodies recognizing surface or intracellular stem cell-associated biomarkers (e.g., Oct4, Nanog, SSEA4, SSEA3, Tra 1–60 and Tra 1–81), using either immuno-histochemistry or flow cytometry. Flow cytometry is a sensitive methodology for the analysis of stem cell populations and their differentiated derivatives as a whole, whilst immuno-histochemistry permits detailed identification and location of markers on specific cells.

### 2.2.2. Pluripotency

Whilst surface and nuclear biomarkers are valuable to confirm hPSC culture identity, they are not sufficient to confirm the pluripotent nature of these cells which requires a pluripotency assay. Recognizing that undifferentiated cells have retained pluripotency is crucial for scientifically robust stem cell research. In early hPSC studies, pluripotency was assessed by teratoma assays in which immunologically compromised mice are injected either subcutaneously or under the kidney capsule to allow the stem cells to differentiate. Whilst this is a powerful research tool it has proved problematic for application in routine quality control (QC) [17] is clearly unacceptable from a 3Rs perspective (i.e. to replace, reduce and refine the use of animals in experimentation), and for some

time alternative in vitro assays have been available [25]. Commonly used in vitro assays include embryoid body (EB) formation, directed differentiation of monolayer cultures and molecular analysis of early stage differentiating cells or even undifferentiated cells to reveal stem cell features [26]. These assays aim to demonstrate that hPSCs are capable of producing cell types representative of all three embryonic germ layers (endodermal, mesodermal and ectodermal, see Fig. 1).

## 2.3. Microbial contamination

The most frequent causes of contamination in cell cultures are bacteria, mycoplasma, yeast and fungi. It is a standard part of current good practice in stem cell banks to carry out routine microbiological controls of the stem cell lines [17,21] and to work with appropriate controlled environments and procedures to reduce the probability of contamination in stem cell cultures. Inoculation of cell culture samples into traditional culture media or testing samples using 16 s RNA PCR can be used to detect bacteria and fungi; however, specialist growth methods and/or staining techniques are needed in order to identify mycoplasma contamination. Contamination of hPSCs with serious viral pathogens appears to be very rare in the experience of stem cell banks. However, it is considered an important safety precaution (for lab worker safety) to test the donors and/or the derived hPSC lines for viruses such as hepatitis C, hepatitis B, human immunodeficiency virus, Epstein-Barr virus and other viruses (including SARS-Cov-2), taking into consideration the historical risks to which donors or cells have been exposed [17].

## 2.4. Genetic state and stability

It is well established that stem cell cultures can suffer from the appearance of variants with a range of types of genetic change, from point mutations to chromosomal amplification, deletion, inversion and translocation [24]. Genetic status and stability can be assessed by a range of techniques including karyology, comparative genomic hybridization, shallow or deep DNA sequencing and array-based single

**Table 2**  
hPSC-derived endodermal cells/tissues.

Cell type	Key morphological, biochemical and functional parameters (or endpoints <sup>a</sup> ) to characterize the model	Technology readiness level (i.e., Low, Medium or High) <sup>b</sup>	References for exemplary protocols for model and measured endpoints
Gastric	The foregut, from which the stomach derives, is marked by the expression of Sox2, whereas the midgut and hindgut express Cdx2	Low	[82]
Pancreatic islet-like cells	Contains 'chief' cells, mucus neck cells, parietal cells, mucus pit cells High % of PDX1 and NKX6.1 positive cells High % of insulin expression `Single hormone (e.g. insulin, glucagon, somatostatin) positive Glucose-responsive, insulin-secreting	High (currently undergoing clinical trials)	[83] [42–88]
Intestinal	CDX2+ cells Contains intestinal mesenchyme and epithelium (enterocytes, goblet cells, Paneth cells, tuft cells, enteroendocrine cells) Crypt-villus architecture Posterior HOX genes	Medium	[89–91]
Liver (Hepatocytes)	Becomes more adult-like after transplantation Stable and long-term expression of mature hepatic markers (CYP3A4, ALB); significantly decreased expression of immature markers (AFP), HTS-LiverTox-verified,	Medium/High	[93]
	Direct comparison with primary hepatocytes, elevated levels of albumin secretion and urea synthesis,	Medium	[94]
	sustained metabolism of Terfenadine and production of Fexofenadine over long term culture		
	iPSC-hepatocytes have shown 65% sensitivity and 100% specificity in the long-term drug toxicity assessment; high levels of albumin secretion, urea synthesis and CYP3A4 activity	Medium	[95]
	Elevated expression levels of HNF4a, ALB, TTR, robust CYP (1A2, 2B6, 3A4) induction, lobular organization	Medium	[96,97]
	Long term expression of ALB, CYP3A4, RBP4 and decreased AFP levels	Low	[98]
	Increased expression of ALB, HNF4a, CYP3A4, CYP2C19, CYP2D6, ASGPR1; albumin secretion in vitro and in vivo	Low	[99]
	Expression of adult isoform of HNF4a, expression of ALB, LXR, UGT1A1, FAH, no expression of AFP; high levels of urea secretion	Low	[100]
Liver (Cholangiocytes)	Mature biliary markers Appearance of cystic and ductal structures Bile acids transfer, responses to secretin, somatostatin	Medium	[101,102] [104]

(continued on next page)

**Table 2** (continued)

Cell type	Key morphological, biochemical and functional parameters (or endpoints <sup>a</sup> ) to characterize the model	Technology readiness level (i.e., Low, Medium or High) <sup>b</sup>	References for exemplary protocols for model and measured endpoints
Bronchus and lungs	Epithelial functions (e.g. presence of CFTR) <b>Proximal lung progenitors</b> FOXJ1, SOX2, ARL13B  <b>Distal lung progenitors</b> FOXP2, SOX9, SPC	High	[63] [104,105]

<sup>a</sup> ‘low’: available protocol(s) is(are) reliable but still at an early stage of development (i.e., lacking well developed key parameters and/or assay).

<sup>b</sup> ‘medium’: available protocol(s) is(are) reliable and reproducible but mainly suitable for research;

‘high’: available protocol(s) is(are) reliable and reproducible and potentially suitable for industry or regulatory use.

<sup>a</sup> An ‘endpoint’ is any feature or parameter to analyse to characterize the cellular model.

<sup>b</sup> Column ‘Technology readiness level’ describes the degree of development of currently available cell culture protocols.

nucleotide polymorphisms (SNPs). Karyology and array SNP are probably the most common techniques used in stem cell banks, but PCR for detection of common chromosomal changes is also becoming more frequently used.

The sustained expression of reprogramming vectors following generation of an iPSC can affect the capacity of a cell line to differentiate and thus, it is important to test hiPSCs to ensure such expression does not persist. This is known to be a feature of a small proportion of hiPSCs generated by non-integrating Sendai virus vectors [25]. Detection of retention of reprogramming vectors can be performed by antibody-based detection or qPCR.

Epigenetic changes are important for normal stem cell functionality, given that during cell differentiation, methylation silences pluripotency genes and demethylation activates expression of certain genes for differentiated cell types. A range of other epigenetic-related changes including histone modification, can also influence the epigenetic landscape of stem cell genomes and their differentiated derivatives. In the future, analysis of such changes may provide valuable quality control tools.

Minimum scientific selection criteria for taking up stem cells for specific applications include the verification of expression of key stemness markers, demonstration of pluripotent capacity (e.g., teratoma assay, embryoid body formation, directed differentiation), microbial contamination data (including mycoplasma testing data) and negative viral safety testing data (of the cell line or human donor).

Questions relating to each of these features should be directed to any cell line suppliers, and sourcing cell lines from well qualified professional sources with a track record in operating best practice, is highly recommended [26]. It is also important to remember that there are important non-scientific factors that will influence the ability to use cell lines, including confirmation of ethical provenance of donor tissue and its use for derivation of cell lines as well as ensuring absence of any donor constraints on use of the cells. In addition, it is also vital to ensure that the cell user is not restricted by conditions of any materials transfer agreement. Such information should be discussed with the provider of the cell line.

Suppliers and user laboratories should be operating a biobanking process which meets best practice for hPSCs. Whilst the core process for biobanking is broadly the same for all applications, there will be different specific criteria for cells to be used for research purposes only [27] compared to those used for developing cell-based medicines [17, 18]. A core quality control testing regime for hPSC banks is outlined in Table 1. More detailed evaluation criteria for different applications can be found in [17,30,31] and a detailed description of development of acceptance criteria used can be found in [18].

Certain quality control criteria should also be checked periodically in the user laboratory for each subsequent cell bank (frozen batch) of cells and for extended passage cells. Priorities in such quality control should include testing for mycoplasma, cell identity and genetic stability [16, 18]. Of the various methods available to test genetic stability, probably the most commonly used for hPSC banking are Giemsa banding karyology, array single nucleotide polymorphisms and qPCR for the most frequent chromosomal variants found in the cultures. These different methods are known to have different benefits and disadvantages and are not necessarily equally efficient at detecting certain kinds of genetic change [22]. Selection of a single method will often involve a compromise between local requirements for sensitivity, specificity, speed, cost and availability of suitable equipment.

### 3. Criteria for hPSC-derived test systems

When working with hPSC-based models it is paramount to assess the quality of the starting culture. In particular, verification of cell viability by e.g., Alamar Blue assay [32], trypan blue exclusion [33] and cell counting before cryopreservation and after thawing of cryopreserved hPSCs should always be performed to ensure consistent seeding of viable

**Table 3**  
hPSC-derived mesodermal cells/tissues.

Cell type	Key morphological, biochemical and functional parameters (or endpoints <sup>a</sup> ) to characterize the model	Technology readiness level <sup>b</sup> (i.e., Low, Medium or High)	References for exemplary protocols for model and measured endpoints
Cardiac cells	<p>With maturation, the shape of the cardiac myocytes changes from round to elongated/anisotropic and the sarcomeric structure becomes well-organized and shows increased sarcomeric length. Some proteins in the sarcomere structure undergo an isoform switch, also observed in human iPSC-derived cardiac myocytes, e.g. <i>TNNI1</i> is expressed in human embryonic cardiac myocytes, but <i>TNNI3</i> (slow skeletal troponin T) is expressed in adult hearts. Similarly, isoform switching of myosin heavy chain (MHC) occurs during development. In humans, <math>\beta</math>-MHC is the predominant isoform in ventricular myocardium, and human PSC-derived cardiac myocytes show increased expression of <math>\beta</math>-MHC and decreased expression of <math>\alpha</math>-MHC during maturation. Electrophysiological properties change during cardiac myocyte maturation: the resting membrane potential in adult cardiac myocytes in heart tissue is <math>\approx -90</math> mV but in human PSC-derived cardiac myocytes it is less negative, probably because of the lower expression of the <math>I_{K1}</math> ion channel. Calcium handling and excitation-contraction coupling are important determinants of the contractile properties of cardiac myocytes.</p> <p><b>Morphology:</b> cobble stone cells</p> <p><b>Markers (1)</b> proximal tubular: LRP2 (aka megalin) and PTH1R (parathyroid hormone 1 receptor) (2) epithelial: TJP3 (aka ZO3) or OCLN (occludin) to indicate polarization of the monolayer</p>	Medium	<p>[106] [48]</p> <p>[107] [108] [109]</p> <p>[110]</p> <p>[111]</p> <p>[112]</p>
Kidney I Renal proximal tubular cells	<p><b>Morphology:</b> cobble stone cells</p> <p><b>Markers (1)</b> proximal tubular: LRP2 (aka megalin) and PTH1R (parathyroid hormone 1 receptor) (2) epithelial: TJP3 (aka ZO3) or OCLN (occludin) to indicate polarization of the monolayer</p>	Low to medium	[112]

**Table 3 (continued)**

Cell type	Key morphological, biochemical and functional parameters (or endpoints <sup>a</sup> ) to characterize the model	Technology readiness level <sup>b</sup> (i.e., Low, Medium or High)	References for exemplary protocols for model and measured endpoints
	<p><b>Functional endpoints:</b> (1) cAMP increase in response to parathyroid hormone (2) albumin uptake by megalin facilitated endocytosis (3) ABCB1 (aka Pgp) efflux via calcein-AM assay Note: polarization is very critical for proximal tubule; staining of these markers needs to be expressed at the tight junction (rather than cytoplasmic or nuclear)</p>		
Kidney II Renal podocytes	<p><b>Morphology:</b> large cells with typical foot-processes</p> <p><b>Markers:</b> SYNPO (synaptopodin) NPHS1 (aka nephrin), NPHS2 (aka podocin) and WT1 (Wilms tumour 1)</p>	Low to medium	[113,114] [115,120]
Kidney III Renal organoids	<p><b>Functional endpoints:</b> Uptake of albumin <b>Morphology:</b> organoid tubule with multiple renal cell types</p> <p><b>Markers:</b> Podocytes: NPHS1, SYNPO, WT1, PODXL; Proximal tubule: <i>Lotus tetragonolobus</i> lectin (LTL), LRP2, CUBN, HNF4A; loop of Henle: UMOD; collecting duct (AQP2); endothelial cells (PECAM1, SOX17)</p>	Low to medium	[117] [121,122]
Blood	Red blood cells	Low (Generating mature RBCs from hiPSCs is still an inefficient process)	[123,124]
Immune cells	<p><b>Dendritic cells</b> Expression of CD141, TLR3, and chemokine receptor XCR1 Protrusions and veils of cytoplasm</p> <p><b>Macrophages</b> Lipopolysaccharide (LPS) co-receptor CD14 and the pan-leukocyte marker CD45</p> <p><b>T cells</b> CD45RO expression Production of IFN-<math>\gamma</math>, TNF, and IL-2 upon the stimulation Anti-tumor activity</p> <p><b>Natural Killer (NK) cells</b> CD3<sup>+</sup>CD56<sup>+</sup> cells, low affinity Fc<math>\gamma</math> receptor</p>	Medium	[125] [126] [127] [128] [129]

(continued on next page)

**Table 3 (continued)**

Cell type	Key morphological, biochemical and functional parameters (or endpoints <sup>a</sup> ) to characterize the model	Technology readiness level <sup>b</sup> (i.e., Low, Medium or High)	References for exemplary protocols for model and measured endpoints
	CD16 to mediate ADCC, can generally be classified into two major subsets: CD56 <sup>bright</sup> CD16 <sup>+</sup> and CD56 <sup>dim</sup> CD16 <sup>+</sup> . The CD56 <sup>dim</sup> CD16 <sup>+</sup> subset of NK cells is predominantly found in the blood and is highly cytotoxic, while the CD56 <sup>bright</sup> CD16 <sup>+</sup> subset is the main subtype found in the lymph nodes and has only weak cytotoxic potential. NK cell activation is regulated by a balance of signals received by the multitude of membrane bound activating and inhibiting receptors. The inhibitory signals such as KIR and NKG2A can detect MHC molecules from the MHC class I recognizing receptors to decrease NK cell activity. NK cytotoxicity can be induced through sufficient stimulation of activating receptors, including the stress ligand receptor NKG2D, and natural cytotoxic receptors (NCR) Nkp30, Nkp44, and Nkp46.	have progressed into clinical trials. Experience with key marker detection and assay validation, has meant that this process can be quickly progressed. New results for two early-stage studies have reported testing two different types of experimental lymphoma treatments that utilize natural killer cells. Eight of 11 lymphoma patients who received one NK cell therapy, FT516, have shown evidence of a response, as have 10 of 14 given another known as FT596. No serious neurological side effects were reported, and only two Grade 1 or Grade 2 cases of the immune-related adverse events typically associated with other forms of engineered cell therapy were observed. The respective clinical trials numbers are NCT04630769, NCT04363346, NCT04245722, and NCT04555811)	[130,131]  NCT04630769 ( <a href="https://clinicaltrials.gov/ct2/show/NCT04630769?term=NCT04630769&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT04630769?term=NCT04630769&amp;rank=1</a> )
	Critical parameters include:  - Cytotoxicity against K562 cells at an 8:1 E:T ratio ≥ 50%  - Flow cytometry for CD3 <sup>+</sup> CD56 <sup>+</sup> CD45 <sup>+</sup>		NCT04363346 ( <a href="https://clinicaltrials.gov/ct2/show/NCT04363346?term=NCT04363346&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT04363346?term=NCT04363346&amp;rank=1</a> ) NCT04245722 ( <a href="https://clinicaltrials.gov/ct2/show/NCT04245722?term=NCT04245722&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT04245722?term=NCT04245722&amp;rank=1</a> ) NCT04555811 ( <a href="https://clinicaltrials.gov/ct2/show/NCT04555811">https://clinicaltrials.gov/ct2/show/NCT04555811</a> )

**Table 3 (continued)**

Cell type	Key morphological, biochemical and functional parameters (or endpoints <sup>a</sup> ) to characterize the model	Technology readiness level <sup>b</sup> (i.e., Low, Medium or High)	References for exemplary protocols for model and measured endpoints
Connective tissue (fibroblasts)	<b>Markers for fibroblasts</b> Vimentin (VIM), ALCAM, HSP47, Platelet-derived growth factor-beta (PDGFRB) <b>Functional assays (in vitro)</b> Scratch assay, Collagen contraction assay	Medium	<a href="https://www.ncbi.nlm.nih.gov/ncbi/pubmed/36113211">ow/NCT04555811?term=NC T04555811&amp;dr aw=2&amp;rank=1</a> [132,133]
Cartilage and bone	<b>Gene expression on Days 7-21</b> <b>Chondroprogenitor lineage</b> Sry-type HMG box, SOX9, and type II collagen <b>Fully differentiated chondrocytes</b> Col2b, aggrecan, Runx2, type X collagen <b>Morphology:</b> Cellular outgrowths and cartilaginous nodules on Days 14-21 <b>Bone specific markers:</b> Alkaline phosphatase (ALP) activity Collagen type I gene expression	Medium	[134]

‘low’: available protocol(s) is(are) reliable but still at an early stage of development (i.e., lacking well developed key parameters and/or method)

‘medium’: available protocol(s) is(are) reliable and reproducible but mainly suitable for research;

‘high’: available protocol(s) is(are) reliable and reproducible and potentially suitable for industry or regulatory use.

<sup>a</sup> An ‘endpoint’ is any feature or parameter to analyse to characterize the cellular model.

<sup>b</sup> Column ‘Technology readiness level’ describes the degree of development of currently available cell culture protocols.

cells and reliable maintenance of stock cultures.

Moreover, evaluation of cell proliferation and growth rate (e.g., nucleic acid content with propidium iodide, 7-aminoactinomycin-D (7-AAD), Hoechst 33258, Ki67<sup>+</sup> cell percentage, incorporation of bromodeoxyuridine (BrdU) or 5-ethynyl-2'-deoxyuridine (EdU)) should be carried out to enable determination of the likelihood of genetic change, cell culture phenotypic drift, ageing and cell senescence that may all occur as a consequence of extended passaging. It is also important to evaluate the possible impact of viral and/or mycoplasma infections, or issues with cross-contamination, which may all be responsible for inherent variation in the cultured cells (e.g., decrease of growth rate and/or cell metabolism assays) [34].

Appropriate characterization of the phenotypic identity of hPSC derivatives is important especially when working with heterogeneous/mixed cell cultures. This entails knowing cell differentiation capacity over time and the expected final proportions of different cell sub-populations, which should be verified by (quantitative) analysis of specific cell population markers (at gene and/or protein level) and by assessing cell functionality whenever appropriate (e.g., by analysis of spontaneous electrical activity of neuronal cell cultures, spontaneous



**Table 4**  
hPSC-derived ectodermal and reproductive cells/tissues.

Cell type	Key morphological, biochemical and functional parameters (or endpoints)	Technology readiness level (i.e., Low, Medium or High)	References for exemplary protocols for model and measured endpoints
Neural stem cells (NSCs)	Expression of NSC markers (protein and gene expression) (e.g., nestin, Sox1, Sox2, Pax6, etc.)	Medium/High	[134–136]
Glutamatergic neurons	Expression of glutamatergic neuron markers (protein and gene expression) (e.g., VGLUT1, VGLUT2, GluR1, TBR1, TBR2, CTIP2, SATB2, GRIA (glutamate receptor, ionotropic, AMPA), GRIK (glutamate receptor, ionotropic, kainite), GRIN (glutamate receptor, ionotropic, NMDA), etc.)	Medium/High	[137–139]
	Electrophysiology, spike and burst patterns	Medium	[140,141]
GABAergic neurons	Neurotransmitter release Expression of GABAergic neuron markers (protein and gene expression) (e.g., GABA, GAD1/2, GAD67, vGAT (SLC32A1), etc.)	Low Medium	[142] [138,143]
	Electrophysiology, spike and burst patterns	Medium	[144–146]
Dopaminergic neurons	Neurotransmitter release Expression of dopaminergic neuron markers (protein and gene expression) (e.g., TH, NR4A1, NR4A2, NR4A3, DAT, etc.)	Low Medium	[140,141,147] [146,148,149]
	Electrophysiology, spike and burst patterns	Low	[150,151]
	Neurotransmitter release (e.g., induced by KCl stimulation)	Low	[152,153]
Cholinergic neurons	Expression of cholinergic neuron markers (protein and gene expression) (e.g., ChAT, p75NTR, FOXG1, ISL1, LHX8, NKX2.1, ACHE, SLC5A7 (CHT1), NGFR, NTRK1 (TRKA), SLC18A3 (VACHT), etc.)	Low	[154–156]
	Electrophysiology, spike and burst patterns	Low	[154,155]
Astrocytes	Neurotransmitter release Expression of classic astrocytic markers (e.g., Glial fibrillary acidic protein (GFAP), S100 calcium-binding protein $\beta$ (S100 $\beta$ ), N-Myc downstream-regulated gene 2 (NDRG2),	Low High	[155] [157–159]

**Table 4 (continued)**

Cell type	Key morphological, biochemical and functional parameters (or endpoints)	Technology readiness level (i.e., Low, Medium or High)	References for exemplary protocols for model and measured endpoints
	Aldh1L1, GLAST and GLT1)		
	Detection of calcium transients	Low	[159,160]
	Astrocytes activation (cytokines releases and morphological changes)	Medium	[161,162]
	L-glutamate or D-aspartate uptake	Medium	[12–166]
Oligodendrocytes	Expression of oligodendrocyte markers (protein and gene expression) (e.g., OLIG1, NG2, O4, O1, GalC, CNPase, etc.)	High	[167–169]
	Expression of myelin markers (protein, gene expression) (e.g., PLP1, MBP, MOG)	Medium	[167,170,171]
	Image analysis quantification of myelin	Low	[56,170,171]
	Compact myelin sheet studies (electron microscopy)	Low	[172,173]
Microglia/Brain macrophages	Expression of microglia markers (gene expression and protein) (e.g., P2Y12, TMEM)	Medium/Low	[174–177]
	Flow cytometry assessment of CD11b and CD45 (microglia)	Medium/Low	[176,178]
	Expression of markers for brain macrophages (Iba1, Cx3cr1, Trem2, CD68)	Medium/Low	[177–179]
	Phagocytosis assay	Medium/Low	[178,180]
	Microglia activation (cytokines releases and morphological changes)	Medium/Low	[181,182]
<b>Reproductive cells/tissues</b>			
Spermatid	Round morphology, haploid nuclei, polarized acrosin expression	Low/medium	[183]
Sertoli cells	Extended and epithelial morphology; cytoplasmic cytoskeleton staining of KRT18, nuclear staining of SOX9; immunosuppression capability	Medium/high	[184]
Ovarian follicles	Cumulus-oocyte-complex morphology; positive staining of zona pellucida (ZP2) proteins and oocyte-specific proteins (NOBOX)	Medium	[185]

‘low’: available protocol(s) is(are) reliable but still at an early stage of development (i.e., lacking well developed key parameters and/or method).  
 ‘medium’: available protocol(s) is(are) reliable and reproducible but mainly suitable for research;  
 ‘high’: available protocol(s) is(are) reliable and reproducible and potentially

suitable for industry or regulatory use.

- 1) An ‘endpoint’ is any feature or parameter to analyse to characterize the cellular model
- 2) Column ‘Technology readiness level’ describes the degree of development of currently available cell culture protocols.

beating rate of cardiomyocytes, metabolic capacity of hepatocytes, glucose-stimulated insulin secretion of pancreatic beta cells etc.; see [Tables 2–4](#)). Hence, key morphological, biochemical and functional parameters (or endpoints) should be selected and acceptance criteria defined to characterize final cell composition of differentiated cell cultures, depending on the intended goals of the study (‘fit-for-purpose’ principle).

Numerous studies have been published describing protocols to obtain well-characterized hPSC-derived ectodermal, mesodermal and endodermal cell types as well as reproductive cells and tissues suitable for different purposes and different contexts of use, both for biomedical research as well as toxicity testing. One common approach in this process is to allow hPSCs to form embryoid bodies (EBs) in suspension using techniques such as ultra-low attachment culture dishes [33], AggreWell™ plates [36]. EBs can then differentiate further to form more mature cells of all three lineages, ectoderm, mesoderm, and endoderm, and be directed by activating or repressing specific signaling pathways which closely mimics the gastrulation phase of development in an embryo. It is also important to note that there is an ever-increasing number of protocols describing differentiation directly to the end cell type of interest, bypassing EB formation, including differentiation of hPSC directly to neurons, muscles, hepatocytes or pancreatic cells [37]. There are also protocols for differentiation of hPSCs to neuroprogenitor cells in monolayer by dual SMAD inhibition which bypass EB and neural rosette formation [3].

However, this large number of cell culture protocols significantly differ in their readiness level for industrial or therapeutic applications, showing variable degrees of development. In particular, some of the most common and relevant morphological, biochemical and functional endpoints can be used as acceptance criteria for the characterization of several hPSC derivatives, as shown in [Tables 2–4](#). On the basis of expert judgment, the technology readiness level of cell culture protocols can be scored as:

- ‘low’ when procedure(s) is(are) well-described and reliable, although still at an early stage of development (i.e., lacking well developed key assessment parameters and/or methods);
- ‘medium’ when available protocol(s) is(are) reliable and reproducible but are still at the developmental stage in basic or applied research; or
- ‘high’ when available protocol(s) is(are) reliable and demonstrated to be reproducible and could be potentially suitable for industry or regulatory use.

It should be considered that technology in this field is rapidly evolving, with cell culture applications expanding across multidisciplinary fields. While the (non-exhaustive) list of parameters and associated readiness level scores shown in [Tables 2–4](#) is not exhaustive and is expected to evolve with time, it serves as a basis to identify possible knowledge gaps and prioritize actions for new protocol design and implementation efforts.

#### 4. Complexity of the applied model: 2D versus 3D

*In vitro* models of developmental processes are frequently used to advance mechanistic understanding of cell differentiation, migration, growth, and final maturation (both morphological and functional), all of which are impacted by their biochemical and biomechanical microenvironment [39]. Deciphering the underlying mechanisms is vital to understand *in vivo* processes that result in formation and function of

tissues and organs and how these processes might be altered under exposure to natural or industrial chemicals or drugs (toxicity testing).

For over a century, two-dimensional (2D) cell cultures have been used as *in vitro* models to study cellular responses to stimulation by biophysical and biochemical cues, as well as for toxicity evaluation induced by exposure to a xenobiotic.

Cells cultured in 2D cell systems typically grow on flat plastic surfaces, sometimes treated to increase adhesive properties to enhance cell attachment and spreading. Although 2D cell culture has been the most common format for most cell culture purposes including toxicity testing, it typically generates compromised systems lacking key components of tissue architecture, cellular interaction and density. This significantly limits the possibility to replicate *in vivo* functionality of a given tissue or organ. Thus, 2D systems might not always be truly representative of real tissue environments, and this can increase the cost and failure rate when either developing new drug discovery platforms in clinical trials, or when carrying out risk and hazard assessment of chemicals.

Despite missing histoarchitecture and limited cell-to-cell interaction, 2D cell cultures are still used for the majority of *in vitro* work because they are inexpensive, well established, can typically be adapted for high throughput purposes, are amenable to comparing new results with previous studies, and are typically easier to process for analysis. All the classical endpoints used for toxicity testing were historically developed to use with monolayer cell cultures and, thus, are very well established for 2D systems. For instance, toxicity testing for the heart using monolayer 2D cultures of hPSC-cardiomyocytes is widely accepted even for regulatory purposes [40]; however, this is not always the case for hazard identification/characterization or risk assessment for kidney, brain and other organs.

Moreover, 2D cultures are widely used to gain understanding of underlying molecular mechanisms and signaling pathways where all parameters can be more readily controlled due to the simpler experimental set-ups. Monolayer 2D cultures of hPSCs differentiated into various cell types are now increasingly used for clinical and toxicological studies. For instance, hiPSC-derived pancreatic cells on platforms are being used to study gene-environment interactions that impact human  $\beta$ -cells and the survival of dopamine neurons [41]. hiPSC-derived neural progenitor cells, differentiated into neuronal or glial derivatives can be used for semi high-throughput toxicity testing where cellular readouts are evaluated including cell viability, immune-cytochemical quantitative expression of neuronal and glial markers or neuronal activity using microelectrode arrays (MEA) [42–45]. High throughput testing programs such as ToxCast and Tox21 have also used mainly monolayer test systems (<https://www.epa.gov/chemical-research/toxcast-data-generation-overview-toxcast-assays>) (<https://ncats.nih.gov/tox21/projects/assays>). However, the strategic plans and developments in this program are moving now towards more complex 3 dimensional (3D) organotypic cultures [46].

Much better biomimetic tissue models make 3D cell cultures more physiologically relevant than 2D cultures. 3D cultures also show a higher degree of structural complexity and retain a “steady state” (homeostasis) for longer [47] and may benefit from more complex mixed cell culture methods [48].

3D cell models present the advantage to model *in vitro* cell micro-environment and cyto-architecture resulting in cell/tissue physiology similar to conditions in the human body [49]. For these reasons scientific focus began to shift to 3D cell cultures more than 30 years ago, starting from the hanging drop method which [50,51] was adapted to *in vitro* differentiation of mouse embryonic stem cells [52]. This method allowed further improvements to a range of scientific studies including the study of embryology, reproductive/developmental toxicology, virology and genetics. However, in spite of this long history, 3D cultures only began to make rapid progress in the late 2000 s

3D cell culture techniques such as spheroids and organoids are now intensively investigated, especially in stem cell research and a broader range of techniques are currently available to generate 3D test systems.

These include the use of extracellular matrices, scaffolds, multi-layering techniques, cell aggregation by gravity, stirring or shaking approaches maintaining cells in ultra-low adherence vessels, microfluidics devices, or bioprinting. These systems have been widely reviewed [53–55] as has the use of 3D organotypic cultures for toxicity testing which was recently summarized by Matsui et al. (2021) [56]. An example of a recent success in this area is the method to generate 3D neurospheres from neural progenitor cells derived from hiPSCs or fetal primary neurons. These are already used for developmental neurotoxicity testing, to assess cell proliferation, migration, differentiation, and other key neurodevelopmental endpoints for regulatory purposes [18,19,57–62].

3D not only promotes the opportunity for better intracellular interactions and survival but also a better functionality. For example, it is hard to develop a co-culture of neurons and oligodendrocytes with active myelination, but differentiation towards myelinating oligodendrocytes can easily be achieved using 3D neurospheres, compensating for the limitation of using 2D monolayer cultures [57]. These 3D neurospheres enable robust differentiation towards both neuronal and glial cell populations, including myelination and formation of more mature neuronal network activity when compared to 2D monolayer culture [19, 57,63].

Moreover, interactions between different types of cells in these complex systems can be facilitated using microfluidics and organ-on-chip (OoC) devices [62]. The first microfluidic microphysiological systems were developed more than 15 years ago and are nowadays generally considered suitable to mimic human patho-biology/physiology because they incorporate options for microfluidic flow as in the case of blood vessels for example, thus providing alternative approaches to the use of laboratory animals in drug development and in basic and applied research [65,66]. Microfluidics systems continuously provide nutrients and cells grow (proliferate, migrate and differentiate) under more physiological conditions. Such systems have also been used for understanding the mechanics of embryonic development [67].

The widespread acceptance and use of such human relevant test systems could ultimately help reduce the reliance on the use of animal models, which have significant limitations in the accurate prediction of how drug treatments or exposure to natural or industrial chemicals and their mixtures will affect animal and human health [68].

However, there are some important issues and obstacles when working with 3D models which need consideration. As mentioned above, some types of readouts (e.g., morphological/structural, immunological, functional) and high content imaging analysis at cellular level were originally developed for monolayer cultures and now need to be adapted for 3D, which can be difficult.

It can also be challenging to distribute oxygen and other essential nutrients to all cells within the spheres/organoids. To avoid such difficulties, the size of 3D culture organoids should be optimized and controlled using scaffold-free systems, such as “hanging drop templates,” “magnetic levitation,” “magnetic 3D bioprinting”, formation of microtissues/organoids, scaffold support (e.g. hydrogel as an extracellular matrix) or vascularization [49].

It is important to note that many 3D culture platforms are still difficult to manipulate, require expertly-trained personnel to handle, are time-consuming, and are still not well standardized and have low reproducibility, thus, rendering them unsuitable for high throughput screening of drugs or chemicals. In addition, the use of hiPSC as a cellular source adds further challenges to achieve reproducibility and standardization, as discussed above. Standardization can help ensure proper characterization of 3D cultures and/or OoC devices, benchmarking using suitable series of reference compounds and ease communication among different stakeholders, for instance by agreeing on terminology and reporting methods [69]. Recently, some initiatives have been undertaken to improve standardization of 3D cultures and OoC using different platforms by introducing key quality controls (biological and technological), with the aim to improve robustness and

reproducibility of these promising new technologies. In particular, the European Commission Joint Research Centre and the European Standardization Organizations CEN and CENELEC in April 2021 organized a workshop titled “Putting Science into Standards”, with the aim of identifying the needs and priorities for developing standards for OoC technologies, spanning selection of materials, chip design, flow rates, etc. Notably, it was concluded that performance assessment, benchmarking, interoperability and qualification of OoC technologies for different contexts of use or applicability domains would benefit from standardization [70]. Standardization will ultimately contribute to the acceleration of regulatory acceptance of these novel technological devices. The National Centre for the Advancement of Translational Science (NCATS) supported initiative toward microphysiological systems international society, calls to support global harmonization and standardization of such technologies. This should accelerate the development and move the 3D cultures and OoC towards regulatory acceptance (<https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-005.html>).

Clearly, the selection of a 2D versus a 3D model is likely to affect the results obtained. For example, 2D models are still more suitable to assess neuronal functionality by analysis of spontaneous electrical activity using traditional multielectrode array platform [63]. However, the fast development of new technologies, and increasing number of new bio-engineered devices more suitable for electrophysiological recordings in 3D [71–74] might change that.

## 5. Test system validation

The principles described in Good Cell Culture Practice (GCCP 2.0) [18] give guidance to scientists as to how to obtain and record, cell and tissue culture information mainly from in vitro methods using new approaches and methods with the most advanced research and innovation test systems, such as hiPSC-derived advanced cell culture models and microphysiological systems. As defined by the FDA, “a microphysiological system (MPS) uses microscale cell culture platform for in vitro modeling of functional features of a specific tissue or organ of human or animal origin by exposing cells to a microenvironment that mimics the physiological aspects important for their function or pathophysiological condition. MPS design may aim to provide and support cultured cells with physical (e.g., temperature, pH and oxygen)/biochemical/electrical/mechanical (e.g., flow or stretch)/structural/morphological conditions and recapitulate a set of specific properties that define a healthy or diseased organ or tissue function. MPS platforms may comprise mono-cultures, co-cultures of multiple cell types, maintenance of explants derived from tissues/organs, and/or inclusion of organoid cell formations. Organ-on-a-chip is a subset class of microphysiological systems and consists of a miniaturized physiological environment engineered to yield and/or analyze functional tissue units capable of modeling specified/targeted organ-level responses” (<https://www.fda.gov/science-research/about-science-research-fda/advancing-alternative-methods-fda>).

The internationally recognized OECD guidance document on Good in Vitro Method Practice (GIVIMP) [16] is intended to support method developers and end-users working to establish new in vitro assays in academic, industry or government laboratories across all 38 OECD member countries and beyond.

In toxicology, stem cell-based in vitro methods are designed to identify potentially harmful effects of chemicals used in a variety of contexts including consumer goods, industrial processes and plant protection products. They are fast becoming key tools for a new way of doing toxicology without resorting to animal testing. Test data derived from in vitro methods are increasingly being used in combination with other information within Integrated Approaches to Testing and Assessment (IATA) to support safety decisions. However, consensus good practice is essential to ensure that in vitro data can be trusted by industry end-users and regulatory authorities for the protection of workers, consumers and the environment. Moreover, in vitro methods that undergo validation often require improvements in their design and

implementation before they can be evaluated regarding their reliability and relevance for a particular regulatory purpose. It is strongly recommended to take careful consideration of GIVIMP requirements during the development of in vitro methods as this will help improve the quality of submitted methods, accelerate their acceptability and ultimately enhance the efficiency of validation studies.

The development of GIVIMP was coordinated by the European Commission Joint Research Centre within the context of a project of the OECD Test Guidelines Program. A large number of international experts, including members of a dedicated OECD expert group and the European Union Network of Validation Laboratories (EU-NETVAL), contributed to the state-of-the-art knowledge gathered within the guidance document. GIVIMP also benefitted from a number of written commenting rounds and two expert meetings before its final endorsement by the OECD's working party for national coordinators of the test guidelines program in April 2018.

Elements described in GIVIMP that are important for the description of in vitro methods using complex stem cell and tissue-based test systems and reporting of derived results are described in detail in the GIVIMP test system chapter. Any stem cell researcher or in vitro method developer is prompted to provide information about the actual stem cells used to arrive at the measurements, the detection method, the method used for dose selection, control and reference chemicals used, specific experimental conditions, data analysis, acceptance criteria applied, validity of the data and reporting of results. It is anticipated that validation bodies and regulatory agencies will expect adherence to GIVIMP to ensure that the proposed stem cell-based method is fit for validation and, ultimately, regulatory acceptance. Regulatory bodies, validation authorities, method developers, and industry toxicologists realize the need to increase confidence in the scientific validity of novel in vitro methods with stem cell-based test systems – especially those being proposed for regulatory application [75,76]. Also, data reviewers such as companies and regulatory agencies responsible for product registrations, will have increased confidence in data generated in laboratories adhering to GIVIMP standards [77] when using stem cells. OECD issued also a specific OHT201 template (<https://www.oecd.org/ehs/templates/harmonized-templates-intermediate-effects.htm>) that can be completed in compliance with GCCP as part of GIVIMP when in vitro mechanistic New Approach Methodologies (NAMs) are reported. The template offers the possibility to declare that GIVIMP guidance was followed and that all elements important for the in vitro method are reported and/or documented (as listed in the template's 'helptext'). To verify that all aspects of the GIVIMP guidance are implemented including all relevant GCCP aspects [18] stem cell researchers, in vitro laboratories and routine testing facilities (e.g., national, EU and international experimental reference laboratory networks) may find it useful to consult the GIVIMP e-learning module from the European Commission <https://etplas.eu/lessons/nuno-lesson/> or the GIVIMP Certification Program which provide guidance on implementation of the quality principles [78]. Good Laboratory Practice (GLP) [79] and Good Cell Culture Practice (GCCP) [18,80] are important topics to consider, but for regulatory submissions in the area of compound safety, GIVIMP serves as a comprehensive quality framework for the development or execution of in vitro methods.

## 6. Conclusions and future considerations

It is clear that the crucial stages at which the scientific reproducibility of hPSC-based model systems can be enhanced are the originally isolated or generated hPSCs, standardized cultures of undifferentiated cells and differentiated cultures representing in vitro assay substrates. In this paper we have outlined the key techniques for the characterization and QC of undifferentiated hPSC cell lines and reviewed the range of methods that may be applied to some representative differentiated hPSC derivatives and their technology readiness level for their application in toxicology. The importance of GCCP, its uptake and utility have been

demonstrated in a recent publication by Tigges et al. [81], which provides recommendations for the implementation of GCCP in the quality control of hiPSCs used in academic research. Of course, there are new analytical developments that will continue to offer potential improvements in functional readouts for hPSC-based systems and it is vital for researchers to keep abreast of these new technologies. In particular, it is highly likely that key areas where technology will develop rapidly will be the application of 3D-cultures, micro-physiological systems and hPSC-derived organoids. It is also likely that use of these systems will reveal new biomarkers and possibilities for enhanced functional assays. However, it is important to consider that with all these dynamic scientific possibilities, it will be essential to keep the principles of GCCP and requirements of GIVIMP in mind so that transition of new and exciting research methods into practical application in toxicology can be made effectively and efficiently.

## Declaration of Competing Interest

The authors have no conflict of interest to declare.

## Data Availability

No data was used for the research described in the article.

## Acknowledgments

We acknowledge support on the figure from Vito D'Alessandro, Università del Salento, Lecce, Italy. We also acknowledge the funding of GS by the Chinese Academy of Sciences President's International Fellowship for Special Experts GRANT No. 2018FSB0009.

## References

- [1] J.A. Thomson, J. Itskovitz-Eldor, S.S. Shapiro, M.A. Waknitz, J.J. Swiergiel, V. S. Marshall, J.M. Jones, Embryonic stem cell lines derived from human blastocysts, *Science* 282 (5391) (1998) 1145–1147.
- [2] K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, S. Yamanaka, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, *Cell* 131 (5) (2007) 861–872.
- [3] H. Inoue, S. Yamanaka, The use of induced pluripotent stem cells in drug development, *Clin. Pharmacol. Ther.* 89 (5) (2011) 655–661.
- [4] V.K. Singh, M. Kalsan, N. Kumar, A. Saini, R. Chandra, Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery, *Front. Cell. Dev. Biol.* 3 (2015) 2.
- [5] A.L. Luz, E.J. Tokar, Pluripotent stem cells in developmental toxicity testing: a review of methodological advances, *Toxicol. Sci.* 165 (1) (2018) 31–39.
- [6] S. Coecke, Amalia Munoz, Vito D'Alessandro, Francesca De Bernardi, Pietro Romeo, Felipe Torres, Georgina Harris, Surat Parvatam, Knowledge from human relevant cell, tissue and mathematics-based methods as key tools for understanding COVID-19. *Chemistry World*, Royal Society Chemistry Books, 2021.
- [7] S. Funakoshi, Y. Yoshida, Recent progress of iPSC technology in cardiac diseases, *Arch. Toxicol.* 95 (12) (2021) 3633–3650.
- [8] Y. Sakai, S. Okuzono, C.P. Schaaf, S. Ohga, Translational pediatrics: clinical perspective for Phelan-McDermid syndrome and autism research, *Pediatr. Res.* (2021).
- [9] J. Kaindl, B. Winner, Disease modeling of neuropsychiatric brain disorders using human stem cell-based neural models, *Curr. Top. Behav. Neurosci.* 42 (2019) 159–183.
- [10] J.R. Millman, F.W. Pagliuca, Autologous pluripotent stem cell-derived  $\beta$ -like cells for diabetes cellular therapy, *Diabetes* 66 (5) (2017) 1111–1120.
- [11] K.G. Maxwell, J.R. Millman, Applications of iPSC-derived beta cells from patients with diabetes, *Cell Rep. Med.* 2 (4) (2021), 100238.
- [12] V. Volpato, C. Webber, Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility, *Dis. Model. Mech.* 13 (1) (2020).
- [13] J.W. Chan, A.K.K. Teo, Replicates in stem cell models-How complicated!, *Stem Cells* 38 (9) (2020) 1055–1059.
- [14] J. Halliwell, I. Barbaric, P.W. Andrews, Acquired genetic changes in human pluripotent stem cells: origins and consequences, *Nat. Rev. Mol. Cell Biol.* 21 (12) (2020) 715–728.
- [15] A. Krebs, T. Waldmann, M.F. Wilks, B.M.A. Van Vugt-Lussenburg, B. Van der Burg, A. Terron, T. Steger-Hartmann, J. Ruegg, C. Rovida, E. Pedersen, G. Pallocca, M. Luijten, S.B. Leite, S. Kustermann, H. Kamp, J. Hoeng, P. Hewitt, M. Herzler, J.G. Hengstler, T. Heinonen, T. Hartung, B. Hardy, F. Gantner, E. Fritsche, K. Fant, J. Ezendam, T. Exner, T. Dunkern, D.R. Dietrich, S. Coecke, F. Busquet, A. Braeuning, O. Bondarenko, S.H. Bennekou, M. Beilmann, M. Leist,

- Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data, *Altox* 36 (4) (2019) 682–699.
- [16] OECD. Guidance Document on Good In Vitro Method Practices (GIVIMP), OECD Series on Testing and Assessment, OECD Publishing, Paris, 2018.
- [17] P.W. Andrews, D. Baker, N. Benvenisty, B. Miranda, K. Bruce, O. Brüstle, M. Choi, Y.M. Choi, J.M. Crook, P.A. de Sousa, P. Dvorak, C. Freund, M. Firpo, M.K. Furue, P. Gokhale, H.Y. Ha, E. Han, S. Haupt, L. Healy, D.J. Hei, O. Hovatta, C. Hunt, S. M. Hwang, M.S. Inamdar, R.M. Isasi, M. Jaconi, V. Jekerle, P. Kamthorn, M. C. Kibbey, I. Knezevic, B.B. Knowles, S.K. Koo, Y. Laabi, L. Leopoldo, P. Liu, G. P. Lomax, J.F. Loring, T.E. Ludwig, K. Montgomery, C. Mummery, A. Nagy, Y. Nakamura, N. Nakatsujii, S. Oh, S.K. Oh, T. Otonkoski, M. Pera, M. Peschanski, P. Pranke, K.M. Rajala, M. Rao, R. Ruttachuk, B. Reubinoff, L. Ricco, H. Rooke, D. Sipp, G.N. Stacey, H. Suemori, T.A. Takahashi, K. Takada, S. Talib, S. Tannenbaum, B.Z. Yuan, F. Zeng, Q. Zhou, Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCB), *Regen. Med.* 10 (Suppl. 2) (2015) S1–S44.
- [18] D. Pames, M. Leist, S. Coecke, G. Bowe, D.G. Allen, G. Gstraunthaler, A. Bal-Price, F. Pistollato, R.B.M. de Vries, H.T. Hogberg, T. Hartung, G. Stacey, Guidance document on good cell and tissue culture practice 2.0 (GCCP 2.0), *Altox* 39 (2021) 30–70.
- [19] D. Pames, P. Barreras, K. Block, G. Makri, A. Kumar, D. Wiersma, L. Smirnova, C. Zang, J. Bressler, K.M. Christian, G. Harris, G.L. Ming, C.J. Berlinicke, K. Kyro, H. Song, C.A. Pardo, T. Hartung, H.T. Hogberg, A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity, *Altox* 34 (3) (2017) 362–376.
- [20] G. Stacey, Stem cell banking: a global view, *Methods Mol. Biol.* 1590 (2017) 3–10.
- [21] International Stem Cell Banking Initiative, Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes, *Stem Cell Rev. Rep.*, 5(4), 2009, pp. 301–14. (DOI: 10.1007/s12015-009-9085-x).
- [22] O. O'Shea, R. Steeg, C. Chapman, P. Mackintosh, G.N. Stacey, Development and implementation of large-scale quality control for the European bank for induced Pluripotent Stem Cells, *Stem Cell Res.* 45 (2020), 101773, <https://doi.org/10.1016/j.scr.2020.101773>.
- [23] S. Sullivan, G.N. Stacey, C. Akazawa, N. Aoyama, R. Baptista, P. Bedford, A. Bennaceur Griscelli, A. Chandra, N. Elwood, M. Girard, S. Kawamata, T. Hanatani, T. Latsis, S. Lin, T.E. Ludwig, T. Malygina, A. Mack, J.C. Mountford, S. Noggle, L.V. Pereira, J. Price, M. Sheldon, A. Srivastava, H. Stachelscheid, S. R. Velayudhan, N.J. Ward, M.L. Turner, J. Barry, J. Song, Quality control guidelines for clinical-grade human induced pluripotent stem cell lines, *Regen. Med.* 13 (7) (2018) 859–866.
- [24] O. Adewumi, B. Afliatounian, L. Ahrlund-Richter, M. Amit, P.W. Andrews, G. Beighton, P.A. Bello, N. Benvenisty, L.S. Berry, S. Bevan, B. Blum, J. Brooking, K.G. Chen, A.B. Choo, G.A. Churchill, M. Corbel, I. Damjanov, J.S. Draper, P. Dvorak, K. Emanuelson, R.A. Fleck, A. Ford, K. Gertow, M. Gertsenstein, P. J. Gokhale, R.S. Hamilton, A. Hampl, L.E. Healy, O. Hovatta, J. Hyllner, M. P. Imreh, J. Itskovitz-Eldor, J. Jackson, J.L. Johnson, M. Jones, K. Kee, B.L. King, B.B. Knowles, M. Lako, F. Lebrin, B.S. Mallon, D. Manning, Y. Mayshar, R. D. McKay, A.E. Michalska, M. Mikkola, M. Mileikovsky, S.L. Minger, H.D. Moore, C.L. Mummery, A. Nagy, N. Nakatsujii, C.M. O'Brien, S.K. Oh, C. Olsson, T. Otonkoski, K.Y. Park, R. Passier, H. Patel, M. Patel, R. Pedersen, M.F. Pera, M. S. Piekarczyk, R.A. Pera, B.E. Reubinoff, A.J. Robins, J. Rossant, P. Rugg-Gunn, T. C. Schulz, H. Semb, E.S. Sherrer, H. Siemen, G.N. Stacey, M. Stojkovic, H. Suemori, J. Szatkiewicz, T. Turetsky, T. Tuuri, S. van den Brink, K. Vintersten, S. Vuorio, D. Ward, T.A. Weaver, L.A. Young, W. Zhang, Characterization of human embryonic stem cell lines by the International Stem Cell Initiative, *Nat. Biotechnol.* 25 (7) (2007) 803–816.
- [25] C. Buta, R. David, R. Dressel, M. Emgård, C. Fuchs, U. Gross, L. Healy, J. Hescheler, R. Kolar, U. Martin, H. Mikkers, F.J. Müller, R.K. Schneider, A. E. Seiler, H. Spielmann, G. Weitzer, Reconsidering pluripotency tests: do we still need teratoma assays? *Stem Cell Res.* 11 (1) (2013) 552–562.
- [26] ISCI, Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells, *Nat. Commun.* 9 (1) (2018) 1925.
- [27] K. Amps, P.W. Andrews, G. Anyfantis, L. Armstrong, S. Avery, H. Baharvand, J. Baker, D. Baker, M.B. Munoz, S. Beil, N. Benvenisty, D. Ben-Yosef, J. C. Biancotti, A. Bosman, R.M. Brena, D. Brison, G. Caisander, J.M. Camarasa, J. Chen, E. Chiao, Y.M. Choi, A.B. Choo, D. Collins, A. Colman, J.M. Crook, G. Q. Daley, A. Dalton, P.A. De Sousa, C. Denning, J. Downie, P. Dvorak, K. D. Montgomery, A. Feki, A. Ford, V. Fox, A.M. Fraga, T. Frumkin, L. Ge, P. J. Gokhale, T. Golan-Lev, H. Gourabi, M. Gropp, G. Lu, A. Hampl, K. Harron, L. Healy, W. Herath, F. Holm, O. Hovatta, J. Hyllner, M.S. Inamdar, A.K. Irwanto, T. Ishii, M. Jaconi, Y. Jin, S. Kimber, S. Kiselev, B.B. Knowles, O. Kopper, V. Kukhareenko, A. Kuliev, M.A. Lagarkova, P.W. Laird, M. Lako, A.L. Laslett, N. Lavon, D.R. Lee, J.E. Lee, C. Li, L.S. Lim, T.E. Ludwig, Y. Ma, E. Maltby, I. Mateizel, Y. Mayshar, M. Mileikovsky, S.L. Minger, T. Miyazaki, S.Y. Moon, H. Moore, C. Mummery, A. Nagy, N. Nakatsujii, K. Narwani, S.K. Oh, S.K. Oh, C. Olson, T. Otonkoski, F. Pan, I.H. Park, S. Pells, M.F. Pera, L.V. Pereira, O. Qi, G. S. Raj, B. Reubinoff, A. Robins, P. Robson, J. Rossant, G.H. Salekdeh, T.C. Schulz, K. Sermon, J. Sheik Mohamed, H. Shen, E. Sherrer, K. Sidhu, S. Sivarajah, H. Skottman, C. Spits, G.N. Stacey, R. Strehl, N. Strelchenko, H. Suemori, B. Sun, R. Suuronen, K. Takahashi, T. Tuuri, P. Venu, Y. Verlinsky, D. Ward-van Oostwaard, D.J. Weisenberger, Y. Wu, S. Yamanaka, L. Young, Q. Zhou, Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage, *Nat. Biotechnol.* 29 (12) (2011) 1132–1144.
- [28] T.M. Schlaeger, L. Daheron, T.R. Brickler, S. Entwisle, K. Chan, A. Cianci, A. DeVine, A. Ettenger, K. Fitzgerald, M. Godfrey, D. Gupta, J. McPherson, P. Malwadkar, M. Gupta, B. Bell, A. Doi, N. Jung, X. Li, M.S. Lynes, E. Brookes, A. B. Cherry, D. Demirbas, A.M. Tsankov, L.I. Zon, L.L. Rubin, A.P. Feinberg, A. Meissner, C.A. Cowan, G.Q. Daley, A comparison of non-integrating reprogramming methods, *Nat. Biotechnol.* 33 (1) (2015) 58–63.
- [29] G.N. Stacey, L. Healy, The international stem cell banking initiative (ISCB), *Stem Cell Res.* 53 (2021), 102265.
- [30] R. Steeg, S.C. Mueller, N. Mah, B. Holst, A. Cabrera-Socorro, G.N. Stacey, P.A. De Sousa, A. Courtney, H. Zimmermann, EBISC best practice: How to ensure optimal generation, qualification, and distribution of iPSC lines, *Stem Cell Rep.* 16 (8) (2021) 1853–1867.
- [31] S. Sullivan, G.N. Stacey, C. Akazawa, N. Aoyama, R. Baptista, P. Bedford, A. Bennaceur Griscelli, A. Chandra, N. Elwood, M. Girard, S. Kawamata, T. Hanatani, T. Latsis, S. Lin, T.E. Ludwig, T. Malygina, A. Mack, J.C. Mountford, S. Noggle, L.V. Pereira, J. Price, M. Sheldon, A. Srivastava, H. Stachelscheid, S. R. Velayudhan, N.J. Ward, M.L. Turner, J. Barry, J. Song, Quality control guidelines for clinical-grade human induced pluripotent stem cell lines, *Regen. Med.* 13 (7) (2018) 859–866.
- [32] F. Bonnier, M.E. Keating, T.P. Wróbel, K. Majzner, M. Baranska, A. Garcia-Munoz, A. Blanco, H.J. Byrne, Cell viability assessment using the Alamar blue assay: a comparison of 2D and 3D cell culture models, *Toxicol. Vitro* 29 (1) (2015) 124–131.
- [33] G.N. Stacey, S. Coecke, A.B. Price, L. Healy, P. Jennings, A. Wilmes, C. Pinset, M. Ingelman-Sundberg, J. Louise, S. Haupt, D. Kidd, A. Robitski, H.G. Jahnke, G. Lemaire, G. Myatt, Ensuring the quality of stem cell-derived in vitro models for toxicity testing, *Adv. Exp. Med. Biol.* 856 (2016) 259–297.
- [34] D. Pames, A. Bal-Price, C. Chesné, S. Coecke, A. Dinnyes, C. Eskes, R. Grillari, G. Gstraunthaler, T. Hartung, P. Jennings, M. Leist, U. Martin, R. Passier, J. C. Schwamborn, G.N. Stacey, H. Ellinger-Ziegelbauer, M. Daneshian, Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems, *Altox* 35 (3) (2018) 353–378.
- [35] G. Pettinato, X. Wen, N. Zhang, Engineering strategies for the formation of embryoid bodies from human pluripotent stem cells, *Stem Cells Dev.* 24 (14) (2015) 1595–1609.
- [36] J. Antonchuk, Formation of embryoid bodies from human pluripotent stem cells using AggreWell™ plates, *Methods Mol. Biol.* 946 (2013) 523–533.
- [37] Y. Oh, J. Jang, Directed differentiation of pluripotent stem cells by transcription factors, *Mol. Cells* 42 (3) (2019) 200–209.
- [38] S.M. Chambers, C.A. Fasano, E.P. Papapetrou, M. Tomishima, M. Sadelain, L. Studer, Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling, *Nat. Biotechnol.* 27 (3) (2009) 275–280.
- [39] D. Huh, G.A. Hamilton, D.E. Ingber, From 3D cell culture to organs-on-chips, *Trends Cell Biol.* 21 (12) (2011) 745–754.
- [40] B. Fermi, J.C. Hancox, N. Abi-Gerges, M. Bridgland-Taylor, K.W. Chaudhary, T. Colatsky, K. Correll, W. Crumb, B. Damiano, G. Erdemli, G. Gintant, J. Imreedy, J. Koerner, J. Kramer, P. Levesque, Z. Li, A. Lindqvist, C.A. Obejero-Paz, D. Rampe, K. Sawada, D.G. Strauss, J.I. Vandenberg, A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm, *J. Biomol. Screen.* 21 (1) (2016) 1–11.
- [41] T. Zhou, T.W. Kim, C.N. Chong, L. Tan, S. Amin, Z. Sadat Badiyean, S. Mukherjee, Z. Ghazizadeh, H. Zeng, M. Guo, M. Crespo, T. Zhang, R. Kenyon, C.L. Robinson, E. Apostolou, H. Wang, J.Z. Xiang, T. Evans, L. Studer, S. Chen, A hPSC-based platform to discover gene-environment interactions that impact human  $\beta$ -cell and dopamine neuron survival, *Nat. Commun.* 9 (1) (2018) 4815.
- [42] F. Pistollato, D. Carpi, E. Mendoza-de Gyves, A. Paini, S.K. Bopp, A. Worth, A. Bal-Price, Combining in vitro assays and mathematical modelling to study developmental neurotoxicity induced by chemical mixtures, *Reprod. Toxicol.* 105 (2021) 101–119.
- [43] F. Pistollato, E.M. de Gyves, D. Carpi, S.K. Bopp, C. Nunes, A. Worth, A. Bal-Price, Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept, *Environ. Health* 19 (1) (2020) 23.
- [44] S.D. Klapper, P. Garg, S. Dagar, K. Lenk, K. Gottmann, K. Nieweg, Astrocyte lineage cells are essential for functional neuronal differentiation and synapse maturation in human iPSC-derived neural networks, *Glia* 67 (10) (2019) 1893–1909.
- [45] L. Nimitz, J. Hartmann, J. Tigges, S. Masjosthusmann, M. Schmuck, E. Keßel, S. Theiss, K. Köhrer, P. Petzsch, J. Adjaye, C. Wigmann, D. Wiczorek, B. Hildebrandt, F. Bendt, U. Hübenthal, G. Brockerhoff, E. Fritsche, Characterization and application of electrically active neuronal networks established from human induced pluripotent stem cell-derived neural progenitor cells for neurotoxicity evaluation, *Stem Cell Res.* 45 (2020), 101761.
- [46] R.S. Thomas, R.S. Pauls, A. Simeonov, S.C. Fitzpatrick, K.M. Crofton, W. M. Casey, D.L. Mendrick, The US Federal Tox21 program: a strategic and operational plan for continued leadership, *Altox* 35 (2) (2018) 163–168.
- [47] D. Pames, T. Hartung, 21st century cell culture for 21st century toxicology, *Chem. Res. Toxicol.* 30 (1) (2017) 43–52.
- [48] E. Giacomelli, V. Meraviglia, G. Campostrini, A. Cochrane, X. Cao, R.W.J. van Helden, A. Krotenberg Garcia, M. Mircea, S. Kostidis, R.P. Davis, B.J. van Meer, C. R. Jost, A.J. Koster, H. Mei, D.G. Míguez, A.A. Mulder, M. Ledesma-Terrón, G. Pompilio, L. Sala, D.C.F. Salvadori, R.C. Sliker, E. Sommariva, A.A.F. de Vries, M. Giera, S. Semrau, L.G.J. Tertoolen, V.V. Orlova, M. Bellin, C.L. Mummery, Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac

- microtissues and reveal non-cardiomyocyte contributions to heart disease, *Cell Stem Cell* 26 (6) (2020) 862–879, e11.
- [49] K. Duval, H. Grover, L.H. Han, Y. Mou, A.F. Pegoraro, J. Fredberg, Z. Chen, Modeling physiological events in 2D vs. 3D cell culture, *Physiology* 32 (4) (2017) 266–277.
- [50] W. Mueller-Klieser, Three-dimensional cell cultures: from molecular mechanisms to clinical applications, *Am. J. Physiol.* 273 (4) (1997) C1109–C1123.
- [51] R. Bjerkvig, S.K. Steinsvåg, O.D. Laerum, Reaggregation of fetal rat brain cells in a stationary culture system. I: Methodology and cell identification, *Vitr. Cell Dev. Biol.* 22 (4) (1986) 180–192.
- [52] X. Wang, P. Yang, In vitro differentiation of mouse embryonic stem (mES) cells using the hanging drop method, *J. Vis. Exp.* 17 (2008).
- [53] Z. Koledova, 3D cell culture: an introduction, *Methods Mol. Biol.* 1612 (2017) 1–11.
- [54] F. Salari, A. Rosa, Construction of 3D in vitro models by bioprinting human pluripotent stem cells: Challenges and opportunities, *Brain Res.* 1723 (2019), 146393.
- [55] J.M. Crook, E. Tomaskovic-Crook, Bioprinting 3D human induced pluripotent stem cell constructs for multilineage tissue engineering and modeling, *Methods Mol. Biol.* 2140 (2020) 251–258.
- [56] T. Matsui, T. Shinozawa, Human organoids for predictive toxicology research and drug development, *Front. Genet.* 12 (2021), 767621.
- [57] M. Chesnut, H. Paschoud, C. Repond, L. Smirnova, T. Hartung, M.G. Zurich, H. T. Hogberg, D. Pames, Human iPSC-derived model to study myelin disruption, *Int. J. Mol. Sci.* 22 (17) (2021).
- [58] X. Zhong, G. Harris, L. Smirnova, V. Zufferey, R. Sá, F. Baldino Russo, P. C. Baleeiro Beltrao Braga, M. Chesnut, M.G. Zurich, H.T. Hogberg, T. Hartung, D. Pames, Antidepressant paroxetine exerts developmental neurotoxicity in an iPSC-derived 3D human brain model, *Front. Cell. Neurosci.* 14 (2020) 25.
- [59] D. Pames, K. Block, P. Lau, L. Gribaldo, C.A. Pardo, P. Barreras, L. Smirnova, D. Wiersma, L. Zhao, G. Harris, T. Hartung, H.T. Hogberg, Rotenone exerts developmental neurotoxicity in a human brain spheroid model, *Toxicol. Appl. Pharmacol.* 354 (2018) 101–114.
- [60] S. Modafferi, X. Zhong, A. Kleensang, Y. Murata, F. Fagiani, D. Pames, H. T. Hogberg, V. Calabrese, H. Lachman, T. Hartung, L. Smirnova, Gene-environment interactions in developmental neurotoxicity: a case study of synergy between chlorpyrifos and CHD8 knockout in human brainspheres, *Environ. Health Perspect.* 129 (7) (2021) 77001.
- [61] T. Chhibber, S. Bagchi, B. Lahooti, A. Verma, A. Al-Ahmad, M.K. Paul, G. Pendyala, R.D. Jayant, CNS organoids: an innovative tool for neurological disease modeling and drug neurotoxicity screening, *Drug Discov. Today* 25 (2) (2020) 456–465.
- [62] M.P. Schwartz, Z. Hou, N.E. Propson, J. Zhang, C.J. Engstrom, V. Santos Costa, P. Jiang, B.K. Nguyen, J.M. Bolin, W. Daly, Y. Wang, R. Stewart, C.D. Page, W. L. Murphy, J.A. Thomson, Human pluripotent stem cell-derived neural constructs for predicting neural toxicity, *Proc. Natl. Acad. Sci. USA* 112 (40) (2015) 12516–12521.
- [63] C. Nunes, G. Gorczyca, E. Mendoza-de Gyves, J. Ponti, A. Bogni, D. Carpi, A. Bal-Price, F. Pistollato, Upscaling biological complexity to boost neuronal and oligodendroglia maturation and improve in vitro developmental neurotoxicity (DNT) evaluation, *Reprod. Toxicol.* 110 (2022) 124–140 (Under Review).
- [64] M. Mastrangeli, J. van den Eijnden-van Raaij, Organs-on-chip: the way forward, *Stem Cell Rep.* 16 (9) (2021) 2037–2043.
- [65] U. Marx, T. Akabane, T.B. Andersson, E. Baker, M. Beilmann, S. Beken, S. Brendler-Schwaab, M. Cirit, R. David, E.M. Dehne, I. Durieux, L. Ewart, S. C. Fitzpatrick, O. Frey, F. Fuchs, L.G. Griffith, G.A. Hamilton, T. Hartung, J. Hoeng, H. Hogberg, D.J. Hughes, D.E. Ingber, A. Iskandar, T. Kanamori, H. Kojima, J. Kuehl, M. Leist, B. Li, P. Loskill, D.L. Mendrick, T. Neumann, G. Pallocca, I. Rusyn, L. Smirnova, T. Steger-Hartmann, D.A. Tagle, A. Tonevitsky, S. Tsyb, M. Trapecar, B. Van de Water, J. Van den Eijnden-van Raaij, P. Vulto, K. Watanabe, A. Wolf, X. Zhou, A. Roth, Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development, *AlteX* 37 (3) (2020) 365–394.
- [66] A. Roth, Human microphysiological systems for drug development, *Science* 373 (6561) (2021) 1304–1306.
- [67] A. Chaubey, K.J. Ross, R.M. Leadbetter, K.J. Burg, Surface patterning: tool to modulate stem cell differentiation in an adipose system, *J. Biomed. Mater. Res. B Appl. Biomater.* (2008) 70–78.
- [68] G.A. Van Norman, Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? *JACC Basic Transl. Sci.* 4 (7) (2019) 845–854.
- [69] M. Piergiorganni, O. Cangar, S.B. Leite, L. Mian, A. Jenet, R. Corvi, M. Whelan, F. Taucer, A. Ganesh, Putting science into standards workshop on standards for organ-on-chip, *Stem Cell Rep.* 16 (9) (2021) 2076–2077.
- [70] M. Piergiorganni, S.B. Leite, R. Corvi, M. Whelan, Standardisation needs for organ on chip devices, *Lab Chip* 21 (15) (2021) 2857–2868.
- [71] J. Cools, Q. Jin, E. Yoon, D. Alba Burbano, Z. Luo, D. Cuypers, G. Callewaert, D. Braeken, D.H. Gracias, A micropatterned multielectrode shell for 3D spatiotemporal recording from live cells, *Adv. Sci.* 5 (4) (2018), 1700731.
- [72] A.P. Passaro, S.L. Stice, Electrophysiological analysis of brain organoids: current approaches and advancements, *Front. Neurosci.* 14 (2020), 622137.
- [73] H. Li, J. Wang, Y. Fang, Bioinspired flexible electronics for seamless neural interfacing and chronic recording, *Nanoscale Adv.* 2 (8) (2020) 3095–3102.
- [74] A. Kalmykov, C. Huang, J. Bliley, D. Shiwarski, J. Tashman, A. Abdullah, S. K. Rastogi, S. Shukla, E. Mataev, A.W. Feinberg, K.J. Hsia, T. Cohen-Karni, Organ-on-e-chip: three-dimensional self-rolled biosensor array for electrical interrogations of human electrogenic spheroids, *Sci. Adv.* 5 (8) (2019) 0729, eaax0729.
- [75] L. Suter-Dick, P.M. Alves, B.J. Blaauboer, K.D. Bremm, C. Brito, S. Coecke, B. Flick, P. Fowler, J. Hescheler, M. Ingelman-Sundberg, P. Jennings, J.M. Kelm, I. Manou, P. Mistry, A. Moretto, A. Roth, D. Stedman, B. van de Water, M. Beilmann, Stem cell-derived systems in toxicology assessment, *Stem Cells Dev.* 24 (11) (2015) 1284–1296.
- [76] E.A. Patterson, M.P. Whelan, A.P. Worth, The role of validation in establishing the scientific credibility of predictive toxicology approaches intended for regulatory application, *Comput. Toxicol.* 17 (2021), 100144.
- [77] A. Bas, N. Burns, A. Gulotta, J. Junker, B. Drasler, R. Lehner, L. Aicher, S. Constant, A. Petri-Fink, B. Rothen-Valtishausser, Understanding the development, standardization, and validation process of alternative in vitro test methods for regulatory approval from a researcher perspective, *Small* 17 (15) (2021), e2006027.
- [78] A. Ulrey, S. Kolle, R. Landsiedel, E. Hill, How a GIVIMP certification program can increase confidence in in vitro methods, *AlteX* 38 (2) (2021) 316–318.
- [79] OECD, OECD Principles on Good Laboratory Practice (as revised in 1997), 1998.
- [80] S. Coecke, M. Balls, G. Bowe, J. Davis, G. Gstraunthaler, T. Hartung, R. Hay, O. W. Merten, A. Price, L. Schechtman, G. Stacey, W. Stokes, Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice, *Altern. Lab. Anim.* 33 (3) (2005) 261–287.
- [81] J. Tigges, K. Bielec, G. Brockerhoff, B. Hildebrandt, U. Hübenenthal, J. Kapr, K. Koch, N. Teichweyde, D. Wiczorek, A. Rossi, E. Fritsche, Academic application of good cell culture practice for induced pluripotent stem cells, *AlteX* 38 (4) (2021) 595–614.
- [82] A.K. Eicher, H.M. Berns, J.M. Wells, Translating developmental principles to generate human gastric organoids, *Cell Mol. Gastroenterol. Hepatol.* 5 (3) (2018) 353–363.
- [83] T. Seidlitz, B.K. Koo, D.E. Stange, Gastric organoids—an in vitro model system for the study of gastric development and road to personalized medicine, *Cell Death Differ.* 28 (1) (2021) 68–83.
- [84] A. Veres, A.L. Faust, H.L. Bushnell, E.N. Engquist, J.H. Kenty, G. Harb, Y.C. Poh, E. Sintov, M. Gürtler, F.W. Pagliuca, Q.P. Peterson, D.A. Melton, Charting cellular identity during human in vitro  $\beta$ -cell differentiation, *Nature* 569 (7756) (2019) 368–373.
- [85] N.J. Hogrebe, K.G. Maxwell, P. Augsornworawat, J.R. Millman, Generation of insulin-producing pancreatic  $\beta$  cells from multiple human stem cell lines, *Nat. Protoc.* 16 (9) (2021) 4109–4143.
- [86] A. Rezania, J.E. Bruin, P. Arora, A. Rubin, I. Batushansky, A. Asadi, S. O'Dwyer, N. Quiskamp, M. Mojibian, T. Albrecht, Y.H. Yang, J.D. Johnson, T.J. Kieffer, Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells, *Nat. Biotechnol.* 32 (11) (2014) 1121–1133.
- [87] C. Haller, J. Piccand, F. De Franceschi, Y. Ohi, A. Bhoumik, C. Boss, U. De Marchi, G. Jacot, S. Metairon, P. Descombes, A. Wiederkehr, A. Palini, N. Bouche, P. Steiner, O.G. Kelly, R.C.K. M. Macroencapsulated human iPSC-derived pancreatic progenitors protect against STZ-induced hyperglycemia in mice, *Stem Cell Rep.* 12 (4) (2019) 787–800.
- [88] A.D. Aguilnick, D.M. Ambruzs, M.A. Moorman, A. Bhoumik, R.M. Cesario, J. K. Payne, J.R. Kelly, C. Haakmeester, R. Srijemac, A.Z. Wilson, J. Kerr, M. A. Frazier, E.J. Kroon, K.A. D'Amour, Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo, *Stem Cells Transl. Med.* 4 (10) (2015) 1214–1222.
- [89] Q. Yu, U. Kilik, E.M. Holloway, Y.H. Tsai, C. Harmel, A. Wu, J.H. Wu, M. Czerwinski, C.J. Childs, Z. He, M.M. Capeling, S. Huang, I.A. Glass, P.D. R. Higgins, B. Treutlein, J.R. Spence, J.G. Camp, Charting human development using a multi-endodermal organ atlas and organoid models, *Cell* 184 (12) (2021) 3281–3298, e22.
- [90] E.M. Holloway, J.H. Wu, M. Czerwinski, C.W. Sweet, A. Wu, Y.H. Tsai, S. Huang, A.E. Stoddard, M.M. Capeling, I. Glass, J.R. Spence, Differentiation of human intestinal organoids with endogenous vascular endothelial cells, *Dev. Cell* 54 (4) (2020) 516–528, e7.
- [91] A. Daoud, J.O. Múnica, Generation of human colonic organoids from human pluripotent stem cells, *Methods Cell Biol.* 159 (2020) 201–227.
- [92] E. Loffel, L. Brossard, M.M. Mahe, Pluripotent stem cell derived intestinal organoids with an enteric nervous system, *Methods Cell Biol.* 159 (2020) 175–199.
- [93] K. Bircsak, A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®, *Toxicology* 450 (2021), 152667.
- [94] C.E.R. Courtney Sakolish, Yu-Syuan Luo, Alan Valdiviezo, Mark E. Schurdak, Albert Gough, D. Lansing Taylor, Weihsueh A. Chiu, Lawrence A. Vernetti, Ivan Rusyn, Analysis of reproducibility and robustness of a human microfluidic four-cell liver acinus microphysiology system (LAMPS), *Toxicology* (2021).
- [95] D.R.B. Brenton, R. Ware, Salman R. Khetani, Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes, 252–62, *Toxicology* 145 (2015), <https://doi.org/10.1093/toxsci/kfv048>.
- [96] X.Q. Xuanyi Ma, Wei Zhu, Yi-Shuan Li, Suli Yuan, Hong Zhang, Justin Liu, Pengrui Wang, Cheuk Sun Edwin Lai, Fabian Zanella, Gen-Sheng Feng, Farah Sheikh, Shu Chien, Shaochen Chen, Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting, *PNAS* (2016) 2206–2211.
- [97] C. Bernasconi, O. Pelkonen, T.B. Andersson, J. Strickland, I. Wilk-Zasadna, D. Asturiol, T. Cole, R. Liska, A. Worth, U. Müller-Vieira, L. Richert, C. Chesne, S. Coecke, Validation of in vitro methods for human cytochrome P450 enzyme induction: outcome of a multi-laboratory study, *Toxicol. Vitr.* 60 (2019) 212–228.

- [98] Y.-H.H. Seon Ju Mun, Hyo-Suk Ahn, Long-term expansion of functional human pluripotent stem, *Int. J. Stem Cells* (2020), <https://doi.org/10.15283/ijsc20060>. <https://www.ijstemcell.com/journal/view.html?>
- [99] F.O. Shogo Nagata, Minghao Nie, Shoji Takeuchi, 3D culture of functional human iPSC-derived, *PLOS ONE* (2020).
- [100] A.S.-Gea Kazuki Takeishi, Assembly and function of a bioengineered human liver for transplantation generated solely from induced pluripotent stem cells, *Cell Rep.* (2020), <https://doi.org/10.1016/j.celrep.2020.107711>.
- [101] F. Sampaziotis, M.C. de Brito, I. Geti, A. Bertero, N.R. Hannan, L. Vallier, Directed differentiation of human induced pluripotent stem cells into functional cholangiocyte-like cells, *Nat. Protoc.* 12 (4) (2017) 814–827.
- [102] M. Ogawa, S. Ogawa, C.E. Bear, S. Ahmadi, S. Chin, B. Li, M. Grompe, G. Keller, B. M. Kamath, A. Ghanekar, Directed differentiation of cholangiocytes from human pluripotent stem cells, *Nat. Biotechnol.* 33 (8) (2015) 853–861.
- [103] F. Sampaziotis, D. Muraro, O.C. Tysoe, S. Sawiak, T.E. Beach, E.M. Godfrey, S. S. Upponi, T. Brevini, B.T. Wesley, J. Garcia-Bernardo, K. Mahubani, G. Canu, R. Gieseck 3rd, N.L. Berntsen, V.L. Mulcahy, K. Crick, C. Fear, S. Robinson, L. Swift, L. Gambardella, J. Bargehr, D. Ortmann, S.E. Brown, A. Osnato, M. P. Murphy, G. Corbett, W.T.H. Gelson, G.F. Mellis, P. Humphreys, S.E. Davies, I. Amin, P. Gibbs, S. Sinha, S.A. Teichmann, A.J. Butler, T.C. See, E. Melum, C.J. E. Watson, K. Saeb-Parsy, L. Vallier, Cholangiocyte organoids can repair bile ducts after transplantation in the human liver, *Science* 371 (6531) (2021) 839–846.
- [104] A. Jacob, M. Morley, F. Hawkins, K.B. McCauley, J.C. Jean, H. Heins, C.L. Na, T. E. Weaver, M. Vedaie, K. Hurley, A. Hinds, S.J. Russo, S. Kook, W. Zacharias, M. Ochs, K. Traber, L.J. Quinton, A. Crane, B.R. Davis, F.V. White, J. Wambach, J. A. Whitsett, F.S. Cole, E.E. Morrisey, S.H. Guttentag, M.F. Beers, D.N. Kotton, Differentiation of human pluripotent stem cells into functional lung alveolar epithelial cells, *Cell Stem Cell* 21 (4) (2017) 472–488, e10.
- [105] H. Surendran, R. Rajamoorthy, R. Pal, Differentiating human induced pluripotent stem cells (iPSCs) into lung epithelial cells, *Curr. Protoc. Stem Cell Biol.* 49 (1) (2019), e86.
- [106] Y. Yoshida, S. Yamanaka, Induced pluripotent stem cells 10 years later: for cardiac applications, *Circ. Res.* 120 (12) (2017) 1958–1968.
- [107] X. Yang, L. Pabon, C.E. Murry, Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes, *Circ. Res.* 114 (3) (2014) 511–523.
- [108] G. Camprostrini, V. Meraviglia, E. Giacomelli, R.W.J. van Helden, L. Yiangou, R. P. Davis, M. Bellin, V.V. Orlova, C.L. Mummery, Generation, functional analysis and applications of isogenic three-dimensional self-aggregating cardiac microtissues from human pluripotent stem cells, *Nat. Protoc.* 16 (4) (2021) 2213–2256.
- [109] M. Tiburcy, J.E. Hudson, P. Balfanz, S. Schlick, T. Meyer, M.L. Chang Liao, E. Levent, F. Raad, S. Zeidler, E. Wingender, J. Riegler, M. Wang, J.D. Gold, I. Kehat, E. Wettwer, U. Ravens, P. Dierckx, L.W. van Laake, M.J. Goumans, S. Khadjeh, K. Toischer, G. Hasenfuss, L.A. Couture, A. Unger, W.A. Linke, T. Araki, B. Neel, G. Keller, L. Gepstein, J.C. Wu, W.H. Zimmermann, Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair, *Circulation* 135 (19) (2017) 1832–1847.
- [110] C.C. Veerman, G. Kosmidis, C.L. Mummery, S. Casini, A.O. Verkerk, M. Bellin, Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? *Stem Cells Dev.* 24 (9) (2015) 1035–1052.
- [111] D.A. Eisner, J.L. Caldwell, K. Kistamás, A.W. Trafford, Calcium and excitation-contraction coupling in the heart, *Circ. Res.* 121 (2) (2017) 181–195.
- [112] V. Chandrasekaran, G. Carta, D. da Costa Pereira, R. Gupta, C. Murphy, E. Feifel, G. Kern, J. Lechner, A.L. Cavallo, F. Caiment, J.C.S. Kleinjans, G. Gstraunthaler, P. Jennings, A. Wilmes, Generation and characterization of iPSC-derived renal proximal tubule-like cells with extended stability, *Sci. Rep.* 11 (1) (2021) 11575.
- [113] C. Rauch, E. Feifel, G. Kern, C. Murphy, F. Meier, W. Parson, M. Beilmann, P. Jennings, G. Gstraunthaler, A. Wilmes, Differentiation of human iPSCs into functional podocytes, *PLoS One* 13 (9) (2018), e0203869.
- [114] B. Song, A.M. Smink, C.V. Jones, J.M. Callaghan, S.D. Firth, C.A. Bernard, A. L. Laslett, P.G. Kerr, S.D. Ricardo, The directed differentiation of human iPSC cells into kidney podocytes, *PLoS One* 7 (9) (2012), e46453.
- [115] S. Musah, A. Mammoto, T.C. Ferrante, S.S.F. Jeanty, M. Hirano-Kobayashi, T. Mammoto, K. Roberts, S. Chung, R. Novak, M. Ingram, T. Fatanat-Didar, S. Koshy, J.C. Weaver, G.M. Church, D.E. Ingber, Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip, *Nat. Biomed. Eng.* 1 (2017).
- [116] O. Ciampi, R. Iacone, L. Longaretti, V. Benedetti, M. Graf, M.C. Magnone, C. Patsch, C. Xinaris, G. Remuzzi, A. Benigni, S. Tomasoni, Generation of functional podocytes from human induced pluripotent stem cells, *Stem Cell Res.* 17 (1) (2016) 130–139.
- [117] A.Q. Lam, B.S. Freedman, R. Morizane, P.H. Lerou, M.T. Valerius, J.V. Bonventre, Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers, *J. Am. Soc. Nephrol.* 25 (6) (2014) 1211–1225.
- [118] M. Takasato, P.X. Er, H.S. Chiu, B. Maier, G.J. Baillie, C. Ferguson, R.G. Parton, E. J. Wolvetang, M.S. Roost, S.M. Chuva de Sousa Lopes, M.H. Little, Kidney organoids from human iPSC cells contain multiple lineages and model human nephrogenesis, *Nature* 526 (7574) (2015) 564–568.
- [119] H. Tsujimoto, T. Kasahara, S.I. Suetta, T. Araoka, S. Sakamoto, C. Okada, S.I. Mae, T. Nakajima, N. Okamoto, D. Taura, M. Nasu, T. Shimizu, M. Ryosaka, Z. Li, M. Sone, M. Ikeya, A. Watanabe, K. Osafune, A modular differentiation system maps multiple human kidney lineages from pluripotent stem cells, *Cell Rep.* 31 (1) (2020), 107476.
- [120] K.A. Homan, N. Gupta, K.T. Kroll, D.B. Kolesky, M. Skylar-Scott, T. Miyoshi, D. Mau, M.T. Valerius, T. Ferrante, J.V. Bonventre, J.A. Lewis, R. Morizane, Flow-enhanced vascularization and maturation of kidney organoids in vitro, *Nat. Methods* 16 (3) (2019) 255–262.
- [121] K.T. Lawlor, J.M. Vanslambrouck, J.W. Higgins, A. Chambon, K. Bishard, D. Arndt, P.X. Er, S.B. Wilson, S.E. Howden, K.S. Tan, F. Li, L.J. Hale, B. Shepherd, S. Pentoney, S.C. Presnell, A.E. Chen, M.H. Little, Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation, *Nat. Mater.* 20 (2) (2021) 260–271.
- [122] S.V. Kumar, P.X. Er, K.T. Lawlor, A. Motazedian, M. Scurr, I. Ghobrial, A. N. Combes, L. Zappia, A. Oshlack, E.G. Stanley, M.H. Little, Kidney micro-organoids in suspension culture as a scalable source of human pluripotent stem cell-derived kidney cells, *Development* 146 (5) (2019).
- [123] M. Ebrahimi, M. Forouzes, S. Raoufi, M. Ramazii, F. Ghaedrahmati, M. Farzaneh, Differentiation of human induced pluripotent stem cells into erythroid cells, *Stem Cell Res. Ther.* 11 (1) (2020) 483.
- [124] J. Sivalingam, E.Y. Su, Z.R. Lim, A.T.L. Lam, A.P. Lee, H.L. Lim, H.Y. Chen, H. K. Tan, T. Warriar, J.W. Hang, N.B. Nazir, A.H.M. Tan, L. Renia, Y.H. Loh, S. Reuveny, B. Malleret, S.K.W. Oh, A scalable suspension platform for generating high-density cultures of universal red blood cells from human induced pluripotent stem cells, *Stem Cell Rep.* 16 (1) (2021) 182–197.
- [125] P. Sachamit, A.J. Leishman, T.J. Davies, P.J. Fairchild, Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141(+) subset, *Front. Immunol.* 8 (2017) 1935.
- [126] A. Vaughan-Jackson, S. Stodolak, K.H. Ebrahimi, C. Browne, P.K. Reardon, E. Pires, J. Gilbert-Jaramillo, S.A. Cowley, W.S. James, Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium, *Stem Cell Rep.* 16 (7) (2021) 1735–1748.
- [127] S. Iriguchi, Y. Yasui, Y. Kawai, S. Arima, M. Kunitomo, T. Sato, T. Ueda, A. Minagawa, Y. Mishima, N. Yanagawa, Y. Baba, Y. Miyake, K. Nakayama, M. Takiguchi, T. Shinohara, T. Nakatsura, M. Yasukawa, Y. Kassai, A. Hayashi, S. Kaneko, A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy, *Nat. Commun.* 12 (1) (2021) 430.
- [128] A. Fernández, A. Navarro-Zapata, A. Escudero, N. Matamala, B. Ruz-Caracul, I. Mirones, A. Pernas, M. Cobo, G. Casado, D. Lanzarot, C. Rodríguez-Antolín, M. Vela, C. Ferreras, C. Mestre, A. Viejo, A. Leivas, J. Martínez, L. Fernández, A. Pérez-Martínez, Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy, *Cancers* 13 (3) (2021).
- [129] K. Shankar, C.M. Capitini, K. Saha, Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies, *Stem Cell Res. Ther.* 11 (1) (2020) 234.
- [130] A.M. Abel, C. Yang, M.S. Thakar, S. Malarkannan, Natural killer cells: development, maturation, and clinical utilization, *Front. Immunol.* 9 (2018) 1869.
- [131] H. Zhu, D.S. Kaufman, An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells, *Methods Mol. Biol.* 2048 (2019) 107–119.
- [132] A.H.M. Ng, P. Khoshakhlagh, J.E. Rojo Arias, G. Pasquini, K. Wang, A. Swiersy, S. L. Shipman, E. Appleton, K. Kiaee, R.E. Kohman, A. Vernet, M. Dysart, K. Leeper, W. Saylor, J.Y. Huang, A. Graveline, J. Taipale, D.E. Hill, M. Vidal, J.M. Melero-Martin, V. Busskamp, G.M. Church, A comprehensive library of human transcription factors for cell fate engineering, *Nat. Biotechnol.* 39 (4) (2021) 510–519.
- [133] K.J. Hewitt, Y. Shamis, R.B. Hayman, M. Margvelashvili, S. Dong, M.W. Carlson, J.A. Garlick, Epigenetic and phenotypic profile of fibroblasts derived from induced pluripotent stem cells, *PLoS One* 6 (2) (2011), e17128.
- [134] J. Calvo-Garrido, D. Winn, C. Maffezzini, A. Wedell, C. Freyer, A. Falk, A. Wredenber, Protocol for the derivation, culturing, and differentiation of human iPSC-cell-derived neuroepithelial stem cells to study neural differentiation in vitro, *STAR Protoc.* 2 (2) (2021), 100528.
- [135] P. Koch, T. Opitz, J.A. Steinbeck, J. Ladewig, O. Brüstle, A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration, *Proc. Natl. Acad. Sci. USA* 106 (9) (2009) 3225–3230.
- [136] M. Jung, J. Schiller, C. Hartmann, J. Pfeifer, D. Rujescu, Generation of neural stem cells from pluripotent stem cells for characterization of early neuronal development, *Methods Mol. Biol.* 2269 (2021) 233–244.
- [137] C. Cheng, S.A. Reis, E.T. Adams, D.M. Fass, S.P. Angus, T.J. Stuhlmiller, J. Richardson, H. Olafson, E.T. Wang, D. Patnaik, R.L. Beauchamp, D.A. Feldman, M.C. Silva, M. Sur, G.L. Johnson, V. Ramesh, B.L. Miller, S. Temple, K.S. Kosik, B. C. Dickerson, S.J. Haggarty, High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy, *Sci. Rep.* 11 (1) (2021) 17029.
- [138] N. Gunhanlar, G. Shpak, M. van der Kroeg, L.A. Gouty-Colomer, S.T. Munshi, B. Lendemeijer, M. Ghazvini, C. Dupont, W.J.G. Hoogendijk, J. Gribnau, F.M.S. de Vrij, S.A. Kushner, A simplified protocol for differentiation of electrophysiologically mature neuronal networks from human induced pluripotent stem cells, *Mol. Psychiatry* 23 (5) (2018) 1336–1344.
- [139] T. Vazin, K.A. Ball, H. Lu, H. Park, Y. Ataeijannati, T. Head-Gordon, M.M. Poo, D. V. Schaffer, Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer's disease, *Neurobiol. Dis.* 62 (2014) 62–72.
- [140] T. Sasaki, I. Suzuki, R. Yokoi, K. Sato, Y. Ikegaya, Synchronousspike patterns in differently mixed cultures of human iPSC-derived glutamatergic and GABAergic neurons, *Biochem. Biophys. Res. Commun.* 513 (2) (2019) 300–305.

- [141] R.F. Halliwell, H. Salmazadeh, L. Coyne, W.S. Cao, An electrophysiological and pharmacological study of the properties of human iPSC-derived neurons for drug discovery, *Cells* 10 (8) (2021).
- [142] S.Y. Cao, Y. Hu, C. Chen, F. Yuan, M. Xu, Q. Li, K.H. Fang, Y. Chen, Y. Liu, Enhanced derivation of human pluripotent stem cell-derived cortical glutamatergic neurons by a small molecule, *Sci. Rep.* 7 (1) (2017) 3282.
- [143] N. Yang, S. Chanda, S. Marro, Y.H. Ng, J.A. Janas, D. Haag, C.E. Ang, Y.S. Tang, Q. Flores, M. Mall, O. Wapinski, M. Li, H. Ahlenius, J.L. Rubenstein, H.Y. Chang, A.A. Buylia, T.C. Sudhof, M. Wernig, Generation of pure GABAergic neurons by transcription factor programming, *Nat. Methods* 14 (6) (2017) 621–628, 621–62.
- [144] A.X. Sun, Q. Yuan, S. Tan, Y. Xiao, D. Wang, A.T. Khoo, L. Sani, H.D. Tran, P. Kim, Y.S. Chiew, K.J. Lee, Y.C. Yen, H.H. Ng, B. Lim, H.S. Je, Direct induction and functional maturation of forebrain GABAergic neurons from human pluripotent stem cells, *Cell Rep.* 16 (7) (2016) 1942–1953.
- [145] T.G. Kim, R. Yao, T. Monnell, J.H. Cho, A. Vasudevan, A. Koh, K.T. Peeyush, M. Moon, D. Datta, V.Y. Bolshakov, K.S. Kim, S. Chung, Efficient specification of interneurons from human pluripotent stem cells by dorsoventral and rostrocaudal modulation, *Stem Cells* 32 (7) (2014) 1789–1804.
- [146] N. Stanslowsky, A. Haase, U. Martin, M. Naujock, A. Leffler, R. Dengler, F. Wegner, Functional differentiation of midbrain neurons from human cord blood-derived induced pluripotent stem cells, *Stem Cell Res. Ther.* 5 (2) (2014) 35.
- [147] Y. Liu, H. Liu, C. Sauvey, L. Yao, E.D. Zarnowska, S.C. Zhang, Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells, *Nat. Protoc.* 8 (9) (2013) 1670–1679.
- [148] S. Mahajani, A. Raina, C. Fokken, S. Kugler, M. Bahr, Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors, *Cell Death Dis.* 10 (2019) 898.
- [149] K.I. Ishikawa, R. Nonaka, W. Akamatsu, Differentiation of midbrain dopaminergic neurons from human iPSC cells, *Methods Mol. Biol.* 2322 (2021) 73–80.
- [150] X. Yin, J.W. Kim, S. Liu, T.M. Dawson, V.L. Dawson, Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons, *STAR Protoc.* 2 (2) (2021), 100405.
- [151] S. Ronchi, A.P. Buccino, G. Prack, S.S. Kumar, M. Schröter, M. Fiscella, A. Hierlemann, Electrophysiological phenotype characterization of human iPSC-derived neuronal cell lines by means of high-density microelectrode arrays, *Adv. Biol.* 5 (3) (2021), e2000223.
- [152] V. Hook, K.J. Brennan, Y. Kim, T. Toneff, L. Funkelstein, K.C. Lee, M. Ziegler, F. H. Gage, Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons, *Stem Cell Rep.* 3 (4) (2014) 531–538.
- [153] M. Komatsu, S. Konagaya, E.Y. Egawa, H. Iwata, Maturation of human iPSC cell-derived dopamine neuron precursors in alginate-Ca(2+) hydrogel, *Biochim. Biophys. Acta* 1850 (9) (2015) 1669–1675.
- [154] S.S. Muñoz, M. Engel, R. Balez, D. Do-Ha, M.C. Cabral-da-Silva, D. Hernández, T. Berg, J.A. Fifta, N. Grima, S. Yang, I.P. Blair, G. Nicholson, A.L. Cook, A. W. Hewitt, A. Pébay, L. Ooi, A simple differentiation protocol for generation of induced pluripotent stem cell-derived basal forebrain-like cholinergic neurons for Alzheimer's disease and frontotemporal dementia disease modeling, *Cells* 9 (9) (2020) 2018.
- [155] L.A. Crompton, M.L. Byrne, H. Taylor, T.L. Kerrigan, G. Bru-Mercier, J.L. Badger, P.A. Barbuti, J. Jo, S.J. Tyler, S.J. Allen, T. Kunath, K. Cho, M.A. Caldwell, Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling, *Stem Cell Res.* 11 (3) (2013) 1206–1221.
- [156] Y. Hu, Z.Y. Qu, S.Y. Cao, Q. Li, L. Ma, R. Krencik, M. Xu, Y. Liu, Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells, *J. Neurosci. Methods* 266 (2016) 42–49.
- [157] T. Sotelo-Hitschfeld, M.I. Niemeyer, P. Machler, I. Ruminot, R. Lerchundi, M. T. Wyss, J. Stobart, I. Fernandez-Moncada, R. Valdebenito, P. Garrido-Gerter, Y. Contreras-Baeza, B.L. Schneider, P. Aebischer, S. Lengacher, A. San Martin, J. Le Douce, G. Bonvento, P.J. Magistretti, F.V. Sepulveda, B. Weber, L.F. Barros, Channel-mediated lactate release by K(+)-stimulated astrocytes, *J. Neurosci.* 35 (10) (2015) 4168–4178.
- [158] Z. Zhang, Z. Ma, W. Zou, H. Guo, M. Liu, Y. Ma, L. Zhang, The appropriate marker for astrocytes: comparing the distribution and expression of three astrocytic markers in different mouse cerebral regions, *BioMed Res. Int.* 2019 (2019), 9605265.
- [159] V. Soubannier, G. Maussion, M. Chaineau, V. Sigutova, G. Rouleau, T.M. Durcan, S. Stifani, Characterization of human iPSC-derived astrocytes with potential for disease modeling and drug discovery, *Neurosci. Lett.* 731 (2020), 135028.
- [160] N. Leventoux, S. Morimoto, K. Imaizumi, Y. Sato, S. Takahashi, K. Mashima, M. Ishikawa, I. Sonn, T. Kondo, H. Watanabe, H. Okano, Human astrocytes model derived from induced pluripotent stem cells, *Cells* 9 (12) (2020) 2680.
- [161] S. Perriot, A. Mathias, G. Perriard, M. Canales, N. Jonkmans, N. Merienne, C. Meunier, L. El Kassar, A.L. Perrier, D.A. Laplaud, M. Schlup, N. Deglon, R. Du Pasquier, Human induced pluripotent stem cell-derived astrocytes are differentially activated by multiple sclerosis-associated cytokines, *Stem Cell Rep.* 11 (5) (2018) 1199–1210.
- [162] D. Pamies, C. Sartori, D. Schvartz, V. Gonzalez-Ruiz, L. Pellerin, C. Nunes, D. Tavel, V. Maillard, J. Boccard, M. Sanchez, M.G. Zurich, Neuroinflammatory response to TNF $\alpha$  and IL1 $\beta$  cytokines is accompanied by an increase in glycolysis in human astrocytes in vitro, *Int. J. Mol. Sci.* 22 (8) (2021).
- [163] A. Birger, I. Ben-Dor, M. Ottolenghi, T. Turetsky, Y. Gil, S. Sweetat, L. Perez, V. Belzer, N. Casden, D. Steiner, M. Izrael, E. Galun, E. Feldman, O. Behar, B. Reubinoff, Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity, *eBioMedicine* 50 (2019) 274–289.
- [164] S. Mahmoud, M. Gharagozloo, C. Simard, D. Gris, Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release, *Cells* 8 (2) (2019) 184.
- [165] A. Hedegaard, J. Monzon-Sandoval, S.E. Newey, E.S. Whiteley, C. Webber, C. J. Akerman, Pro-maturational effects of human iPSC-derived cortical astrocytes upon iPSC-derived cortical neurons, *Stem Cell Rep.* 15 (1) (2020) 38–51.
- [166] G.K. Gandhi, N.F. Cruz, K.K. Ball, G.A. Diemel, Astrocytes are poised for lactate trafficking and release from activated brain and for supply of glucose to neurons, *J. Neurochem.* 111 (2) (2009) 522–536.
- [167] S. Kuhn, L. Gritti, D. Crooks, Y. Dombrowski, Oligodendrocytes in development, myelin generation and beyond, *Cells* 8 (11) (2019).
- [168] M. Chesnut, T. Hartung, H. Hogberg, D. Pamies, Human oligodendrocytes and myelin in vitro to evaluate developmental neurotoxicity, *Int. J. Mol. Sci.* 22 (15) (2021) 7929.
- [169] D.L. McPhie, R. Nehme, C. Ravichandran, S.M. Babb, S.D. Ghosh, A. Staskus, A. Kalinowski, R. Kaur, P. Douvaras, F. Du, D. Ongur, V. Fossati, K. Eggan, B. M. Cohen, Oligodendrocyte differentiation of induced pluripotent stem cells derived from subjects with schizophrenia implicate abnormalities in development, *Transl. Psychiatry* 8 (2018) 230.
- [170] D. Pamies, M. Chesnut, L. Smirnova, A. Mutallimov, V. Maillard, C. Repond, T. Hartung, M.G. Zurich, H. Hogberg, Human 3D iPSC-derived brain model to study chemical-induced myelin disruption, *Glia* 69 (2021) E392–E394.
- [171] M. Ehrlich, S. Mozafari, M. Glatza, L. Starost, S. Velychko, A.L. Hallmann, Q. L. Cui, A. Schambach, K.P. Kim, C. Bachelin, A. Marteyn, G. Hargus, R. M. Johnson, J. Antel, J. Sternecker, H. Zaehres, H.R. Scholer, A. Baron-Van Evercooren, T. Kuhlmann, Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors, *Proc. Natl. Acad. Sci. USA* 114 (11) (2017) E2243–E2252.
- [172] M.K. Giacci, C.A. Bartlett, M. Huynh, M.R. Kilburn, S.A. Dunlop, M. Fitzgerald, Three dimensional electron microscopy reveals changing axonal and myelin morphology along normal and partially injured optic nerves, *Sci. Rep.* 8 (2018) 3979.
- [173] D. Pamies, P. Barreras, K. Block, G. Makri, A. Kumar, D. Wiersma, L. Smirnova, C. Zhang, J. Bressler, K.M. Christian, G. Harris, G.L. Ming, C.J. Berlinic, K. Kyro, H.J. Song, C.A. Pardo, T. Hartung, H.T. Hogberg, A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity, *Altex-Altern. Anim. Ex.* 34 (3) (2017) 362–376.
- [174] R.J. Xu, X.X. Li, A.J. Boreland, A. Posyton, K. Kwan, R.P. Hart, P. Jiang, Human iPSC-derived mature microglia retain their identity and functionally integrate in the chimeric mouse brain, *Nat. Commun.* 11 (1) (2020) 1577.
- [175] J. Hasselmann, M. Blurton-Jones, Human iPSC-derived microglia: a growing toolset to study the brain's innate immune cells, *Glia* 68 (4) (2020) 721–739.
- [176] A.M. Speicher, H. Wiendl, S.G. Meuth, M. Pawlowski, Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration, *Mol. Neurodegener.* 14 (1) (2019) 46.
- [177] Y. Chen, M. Colonna, Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice? *J. Exp. Med.* 218 (9) (2021).
- [178] P. Garcia-Reitboeck, A. Phillips, T.M. Piets, C. Villegas-Llerena, M. Butler, A. Mallach, C. Rodrigues, C.E. Arber, A. Heslegrave, H. Zetterberg, H. Neumann, S. Neame, H. Houlden, J. Hardy, J.M. Pocock, Human induced pluripotent stem cell-derived microglia-like cells harboring TREM2 missense mutations show specific deficits in phagocytosis, *Cell Rep.* 24 (9) (2018) 2300–2311.
- [179] E.M. Abud, R.N. Ramirez, E.S. Martinez, L.M. Healy, C.H.H. Nguyen, S. A. Newman, A.V. Yeromin, V.M. Scarfone, S.E. Marsh, C. Fimbres, C.A. Caraway, G.M. Fote, A.M. Madany, A. Agrawal, R. Kaye, K.H. Gyllys, M.D. Cahalan, B. J. Cummings, J.P. Antel, A. Mortazavi, M.J. Carson, W.W. Poon, M. Blurton-Jones, iPSC-derived human microglia-like cells to study neurological diseases, *Neuron* 94 (2) (2017) 278–293.e9, 278–27.
- [180] S. Monkley, J.K. Krishnaswamy, M. Goransson, M. Clausen, J. Mueller, K. Thorn, R. Hicks, S. Delaney, L. Stjernborg, Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterparts, *PLoS One* 15 (12) (2020), 0243807.
- [181] C.M. Abreu, L. Gama, S. Krasemann, M. Chesnut, S. Odwin-Dacosta, H. T. Hogberg, T. Hartung, D. Pamies, Microglia increase inflammatory responses in iPSC-derived human brainspheres, *Front. Microbiol.* 9 (2018).
- [182] S.I. Schmidt, H. Bogerofte, L. Ritter, J.B. Agergaard, D. Hammerich, A. A. Kabiljagic, A. Wlodarczyk, S.G. Lopez, M.D. Sorensen, M.L. Jorgensen, J. Okarmus, A.M. Serrano, B.W. Kristensen, K. Freude, T. Owens, M. Meyer, Microglia-secreted factors enhance dopaminergic differentiation of tissue- and iPSC-derived human neural stem cells, *Stem Cell Rep.* 16 (2) (2021) 281–294.
- [183] K. Kee, V.T. Angeles, M. Flores, H.N. Nguyen, R.A. Reijo Pera, Human DAZL, DAZ and BOULE genes modulate primordial germ-cell and haploid gamete formation, *Nature* 462 (7270) (2009) 222–225.
- [184] J. Liang, N. Wang, J. He, J. Du, Y. Guo, L. Li, W. Wu, C. Yao, Z. Li, K. Kee, Induction of Sertoli-like cells from human fibroblasts by NR5A1 and GATA4, *eLife* 8 (2019).
- [185] D. Jung, J. Xiong, M. Ye, X. Qin, L. Li, S. Cheng, M. Luo, J. Peng, J. Dong, F. Tang, W. Shen, M.M. Matzuk, K. Kee, In vitro differentiation of human embryonic stem cells into ovarian follicle-like cells, *Nat. Commun.* 8 (2017) 15680.